[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 544
1. Rendon RA: New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer. Can Urol Assoc J; 2007 Jun;1(2 Suppl):S62-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer.
  • Renal cell carcinoma is the most lethal urologic malignancy.
  • Up to 30% of patients with kidney cancer have metastatic disease and 30% of those treated for local or locally advanced disease will progress to metastases.
  • Radical nephrectomy is the standard treatment for the management of nondisseminated kidney cancer, but the role of cytoreductive nephrectomy for patients with metastatic disease is controversial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1978 Aug;120(2):148-52 [78992.001]
  • [Cites] Br J Urol. 1989 Feb;63(2):128-31 [2702395.001]
  • [Cites] J Urol. 1995 Jul;154(1):35-40 [7539867.001]
  • [Cites] J Urol. 1997 Nov;158(5):1675-8 [9334576.001]
  • [Cites] J Urol. 1997 Nov;158(5):1691-5 [9334580.001]
  • [Cites] J Urol. 1998 Apr;159(4):1168-73 [9507824.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):523-8 [10080595.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1649-57 [11250993.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):966-70 [11583750.001]
  • [Cites] Urology. 2003 Oct;62(4):636-40 [14550433.001]
  • [Cites] Urology. 2003 Dec;62(6):1018-23 [14665347.001]
  • [Cites] J Urol. 2004 Mar;171(3):1071-6 [14767273.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6335S-41S [15448027.001]
  • [Cites] J Urol. 2005 Jun;173(6):1853-62 [15879764.001]
  • [Cites] BJU Int. 2005 Sep;96(4):483-8 [16104896.001]
  • [Cites] Nat Clin Pract Urol. 2004 Nov;1(1):26-30 [16474463.001]
  • [Cites] Urology. 2006 Sep;68(3):528-32 [16979706.001]
  • [Cites] BJU Int. 2006 Dec;98(6):1228-32 [17034508.001]
  • [Cites] J Urol. 2006 Nov;176(5):1990-5; discussion 1995 [17070231.001]
  • [Cites] Urology. 2004 Nov;64(5):930-4 [15533480.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Jan;7(1):73-8 [17187521.001]
  • [Cites] J Urol. 1986 Aug;136(2):376-9 [3735498.001]
  • [Cites] Urology. 1982 Aug;20(2):177-81 [7112827.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Urol. 1995 Jul;154(1):32-4 [7776449.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 1):1399-403 [7933169.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):7-13 [8289458.001]
  • [Cites] Semin Urol Oncol. 1996 Nov;14(4):230-6 [8946623.001]
  • [Cites] J Urol. 1997 Sep;158(3 Pt 1):740-5 [9258071.001]
  • [Cites] Urology. 1999 Mar;53(3):496-501 [10096373.001]
  • [Cites] J Urol. 1999 Dec;162(6):1934-7 [10569541.001]
  • [Cites] Urology. 2000 Jan;55(1):36-40 [10654891.001]
  • [Cites] J Urol. 2001 Jul;166(1):63-7 [11435824.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1711-2 [11759660.001]
  • [Cites] Urology. 2002 Jan;59(1):9-14 [11796271.001]
  • [Cites] BJU Int. 2002 Apr;89(6):523-5 [11942956.001]
  • [Cites] J Urol. 2002 Dec;168(6):2395-400 [12441925.001]
  • [Cites] Urol Clin North Am. 2003 Aug;30(3):581-8 [12953756.001]
  • [Cites] BJU Int. 2003 Dec;92(9):901-5 [14632843.001]
  • [Cites] Urology. 2004 Nov;64(5):925-9 [15533479.001]
  • [Cites] World J Urol. 2005 Jul;23(3):191-5 [15791469.001]
  • [Cites] World J Urol. 2005 Jul;23(3):155-60 [15988593.001]
  • [Cites] J Urol. 1977 Oct;118(4):538-42 [916044.001]
  • (PMID = 18542787.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2422951
  •  go-up   go-down


2. Parsa V, Heilbrun L, Smith D, Sethi A, Vaishampayan U: Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin Genitourin Cancer; 2009 Aug;7(2):E10-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function.
  • PURPOSE: Sorafenib is an oral Raf kinase inhibitor, approved for the treatment of advanced renal cancer.
  • Clinical investigation of the safety and feasibility of sorafenib therapy in patients with impaired renal function was performed in this study.
  • Medical records of patients with metastatic renal cancer at Wayne State University started on sorafenib between November 2005 to January 2007 were reviewed.
  • Patients with a calculated creatinine clearance (CrCl) of 60 mL/min or less (chronic kidney disease stage 3 or greater per Kidney Disease Outcomes Quality Initiative guidelines) were deemed to have renal insufficiency.
  • RESULTS: A total of 32 patients who met the selection criteria were analyzed.
  • Fourteen of 32 (44%) patients had renal insufficiency (range, 32-60 mL/min).
  • Incidence of diarrhea (57% vs. 33%) and hand-foot syndrome (86% vs. 56%) were higher in the renal-dysfunction group.
  • Dose interruptions and dose reductions were noted in 57% and 43% of patients with renal dysfunction versus 28% and 22% in those without.
  • CONCLUSION: Renal insufficiency is frequently observed in patients with advanced renal cancer.
  • Sorafenib therapy can be safely delivered in patients with mild and moderate renal dysfunction, and efficacy appears to be maintained.

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):454-63 [14752067.001]
  • [Cites] Int Urol Nephrol. 2003;35(2):263-5 [15072507.001]
  • [Cites] Urology. 1998 Feb;51(2):203-5 [9495698.001]
  • [Cites] Kidney Int. 2005 Jun;67(6):2089-100 [15882252.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2505-12 [16636341.001]
  • [Cites] World J Urol. 2006 Aug;24(3):255-66 [16479388.001]
  • [Cites] BJU Int. 2006 Aug;98(2):298-302 [16879668.001]
  • [Cites] Int J Urol. 2006 Aug;13(8):1045-8 [16903927.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Oncologist. 2007 Apr;12(4):426-37 [17470685.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):159-65 [17953709.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • (PMID = 19692316.001).
  • [ISSN] 1938-0682
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA022453; United States / NCI NIH HHS / CA / CA-22453
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ NIHMS514487; NLM/ PMC3865860
  •  go-up   go-down


3. Vyas S, Kalra N, Kapoor R, Suri V, Khandelwal N: Bilateral calcified renal metastases from osteosarcoma. Cancer Imaging; 2010;10:124-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral calcified renal metastases from osteosarcoma.
  • Calcified renal metastases from osteosarcoma are extremely rare.
  • We present a case of a young female with osteosarcoma of the right ulna who developed late recurrence in the form of large metastatic calcified renal and pulmonary lesions.
  • Review of the literature suggests that osteosarcoma metastases of the kidneys usually exhibit aggressive behaviour with poor prognosis.
  • A brief review of the calcified renal metastases including the index case is presented.
  • [MeSH-major] Bone Neoplasms / diagnosis. Calcinosis / diagnosis. Kidney Neoplasms / diagnosis. Kidney Neoplasms / secondary. Osteosarcoma / diagnosis. Osteosarcoma / secondary
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Pregnancy. Ulna. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1977 Jan;128(1):148-9 [401574.001]
  • [Cites] J Urol. 1984 Oct;132(4):752-4 [6590875.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2326-31 [3863693.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):690-2 [17226847.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 Aug;18(3):321-2 [8689353.001]
  • [Cites] Jpn J Clin Oncol. 1999 Aug;29(8):395-8 [10494925.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Sep;28(9):618-21 [17006269.001]
  • [Cites] Clin Imaging. 1989 Jun;13(2):154-6 [2670146.001]
  • (PMID = 20529759.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2883782
  •  go-up   go-down


Advertisement
4. Djekidel M, Gordon M, Shah RB, Gross MD, Avram A: Renal metastasis from Hurthle cell thyroid carcinoma and its evaluation with hybrid imaging. Thyroid; 2010 Apr;20(4):429-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal metastasis from Hurthle cell thyroid carcinoma and its evaluation with hybrid imaging.
  • Metastases to other organs are distinctly unusual.
  • Renal metastases have been reported in only 10 patients.
  • Here we report, to the best of our knowledge, the first patient with Hurthle cell thyroid cancer and renal metastasis.
  • Multimodality imaging with fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging, and Somatostatin receptor scintigraphy with single photon emission computed tomography (SPECT)-computed tomography revealed numerous foci in the skeleton and right kidney.
  • Anatomic imaging characteristics favored a primary renal cell cancer with the additional evidence of renal vein invasion and thrombosis.
  • Histology later revealed a metastatic renal Hurthle cell cancer with positive thyroglobulin stains.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Kidney Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Fluorodeoxyglucose F18. Fractures, Bone. Humans. Magnetic Resonance Imaging. Male. Positron-Emission Tomography. Thyroglobulin / analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2010 Nov;20(11):1321; author reply 321-2 [21062198.001]
  • (PMID = 20373987.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


5. Escudier B, Paparel P, Neuzillet Y, Long JA, Rioux-Leclercq N, Correas JM, Lang H, Poissonnier L, Baumert H, Mejean A, Patard JJ: [Treatment of metastatic kidney cancer in elderly subjects]. Prog Urol; 2009 Nov;19 Suppl 3:S129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of metastatic kidney cancer in elderly subjects].
  • [Transliterated title] Traitement du cancer du rein métastatique chez les sujets âgés.
  • Treatment of metastatic kidney cancer in elderly subjects is identical to treatment of younger subjects.
  • Given the data available today, no dose adaptation in relation to age is recommended in metastatic renal cancer.
  • [MeSH-major] Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20123496.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Doehn C: [New drugs for metastatic kidney cancer]. Aktuelle Urol; 2008 Jan;39(1):41-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New drugs for metastatic kidney cancer].
  • Systemic therapy of metastatic kidney cancer has undergone dramatic changes over the past years.
  • Furthermore, signalling pathways have been identified to be relevant for tumour progression and therapeutic intervention.
  • Until some years ago, systemic therapy for kidney cancer consisted of cytokines.
  • In this review, new drugs for the treatment of metastatic kidney cancer are discussed.
  • Four drugs have been studied in phase III trials and were (or will soon be) approved for treatment of metastatic kidney cancer.
  • At present, the following scenarios have an impact on therapy decisions: different prognostic groups, first-line and second-line therapy, combination therapies and the impact of different histological subtypes.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Cytokines / therapeutic use. Disease Progression. Humans. Immunologic Factors / administration & dosage. Immunologic Factors / therapeutic use. Karnofsky Performance Status. Kidney / pathology. Prognosis. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / therapeutic use. Protein Kinases / drug effects. Receptor, Epidermal Growth Factor / drug effects. Risk Factors. Signal Transduction / drug effects. TOR Serine-Threonine Kinases. Time Factors. Vascular Endothelial Growth Factor A / drug effects


7. Patard JJ, Escudier B, Paparel P, Neuzillet Y, Long JA, Baumert H, Correas JM, Lang H, Poissonnier L, Rioux-Leclercq N, Soulié M, le Comité de Cancérologie de l'Association Française d'Urologie (CCAFU): [Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer]. Prog Urol; 2010 Mar;20 Suppl 1:S11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progress and summary of recent congress: ASCO-GU, EAU, AUA, ASCO about the medical management of locally advanced or metastatic kidney cancer].
  • [Transliterated title] Avancées et synthèse des derniers congrès: ASCO-GU, EAU, AUA, ASCO concernant la prise en charge médicale du cancer du rein localement avancé ou métastatique.
  • During the recent congress of urology and oncology key topics discussed were the evolution of survival data in metastatic kidney cancer which median is now around 40 months, persistent questions about the role of nephrectomy, including access to the systemic treatment of nephrectomized patients and tumor resectability induced by systemic therapies, the emergence of new prognostic models which are adapted to new therapeutic standards, and the emergence of promising new drugs including pazopanib.
  • [MeSH-major] Congresses as Topic. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy
  • [MeSH-minor] Disease Progression. Humans. Neoplasm Metastasis. Nephrectomy. Prognosis

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20493436.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Egleston BL, Wong YN: Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data. Stat Med; 2009 May 1;28(10):1498-511
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity analysis to investigate the impact of a missing covariate on survival analyses using cancer registry data.
  • Having substantial missing data is a common problem in administrative and cancer registry data.
  • We apply the method to an investigation of the impact of missing grade on post-surgical mortality outcomes in individuals with metastatic kidney cancer.
  • Tumor grade is an important component of risk stratification for patients with both localized and metastatic kidney cancer.
  • Many individuals in SEER with metastatic kidney cancer are missing tumor grade information.

  • MedlinePlus Health Information. consumer health - Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 John Wiley & Sons, Ltd.
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] Biometrics. 2001 Jun;57(2):414-9 [11414564.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • [Cites] Biostatistics. 2003 Jan;4(1):41-56 [12925329.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3316-22 [15310775.001]
  • [Cites] N Engl J Med. 2005 Jan 13;352(2):154-64 [15647578.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2375-83 [17048248.001]
  • [Cites] JAMA. 2006 Dec 13;296(22):2683-93 [17164454.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):693s-696s [17255295.001]
  • [Cites] Cancer. 2007 Mar 1;109(5):868-74 [17262800.001]
  • [Cites] Biostatistics. 2007 Apr;8(2):345-56 [16840561.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3589-95 [17704406.001]
  • (PMID = 19235263.001).
  • [ISSN] 0277-6715
  • [Journal-full-title] Statistics in medicine
  • [ISO-abbreviation] Stat Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006927; None / None / / P30 CA006927-46; United States / NCI NIH HHS / CA / P30 CA 06927; United States / NCI NIH HHS / CA / P30 CA006927-46
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS115998; NLM/ PMC2741403
  •  go-up   go-down


9. Walker PR, Khuder SA, Quan WD Jr: Continuous infusion interleukin-2 and antihistamines in metastatic kidney cancer. Cancer Biother Radiopharm; 2005 Oct;20(5):487-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous infusion interleukin-2 and antihistamines in metastatic kidney cancer.
  • A prior randomized trial suggested a possible survival advantage favoring the combination of histamine and subcutaneous interleukin-2 (IL-2), compared to IL-2 alone in patients with metastatic melanoma.
  • We sought to determine whether there was any negative effect of the combination in patients with metastatic kidney cancer.
  • In this study of CIV IL-2 and antihistamines, this combination appears to be active in metastatic kidney cancer.
  • [MeSH-major] Histamine H1 Antagonists / therapeutic use. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Antineoplastic Agents / therapeutic use. Cimetidine / therapeutic use. Famotidine / therapeutic use. Histamine / therapeutic use. Histamine H2 Antagonists / therapeutic use. Humans. Neoplasm Metastasis. Ranitidine / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. CIMETIDINE .
  • Hazardous Substances Data Bank. RANITIDINE .
  • Hazardous Substances Data Bank. FAMOTIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16248764.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / Histamine H1 Antagonists; 0 / Histamine H2 Antagonists; 0 / Interleukin-2; 5QZO15J2Z8 / Famotidine; 80061L1WGD / Cimetidine; 820484N8I3 / Histamine; 884KT10YB7 / Ranitidine
  •  go-up   go-down


10. Quan WD Jr, Quan FM: High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. Cancer Biother Radiopharm; 2009 Apr;24(2):181-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer.
  • Lymphokine-activated killer cell (LAK) activity against tumor cell lines may be induced by intravenous (i.v.) interleukin-2 (IL-2).
  • Daily short infusions (pulses) have been developed to decrease toxicity while maintaining the anticancer activity of this agent against kidney cancer.
  • We have treated 12 patients with metastatic kidney cancer, using pulse IL-2 (18 million IU/M(2) i.v.) over 15-30 minutes, preceded by famotidine (20 mg I.V. daily for 5 days) on an oncology inpatient unit.
  • Patient characteristics were as follows: 9 males with a median age of 66 years (range, 48-74), and median Eastern Cooperative Oncology Group performance status of 1; common metastatic sites included in the lungs 9 and lymph nodes 3.
  • Pulse IL-2 with famotidine shows activity in kidney cancer.
  • [MeSH-major] Famotidine / administration & dosage. Histamine H2 Antagonists / adverse effects. Histamine H2 Antagonists / therapeutic use. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cytokine-Induced Killer Cells / drug effects. Cytokine-Induced Killer Cells / immunology. Disease Progression. Drug Administration Schedule. Drug Interactions. Female. Humans. Lymphocytes / drug effects. Lymphocytes / metabolism. Male. Middle Aged. Neoplasm Metastasis. Receptors, Interleukin-2 / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. FAMOTIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409039.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine H2 Antagonists; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 5QZO15J2Z8 / Famotidine
  •  go-up   go-down


11. Quan WD Jr, Vinogradov M, Quan FM, Khan N, Liles DK, Walker PR: Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer. Cancer Biother Radiopharm; 2006 Oct;21(5):515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous infusion interleukin-2 and famotidine in metastatic kidney cancer.
  • Infusional interleukin-2 (IL-2) is able to elicit lymphokine-activated killer cell (LAK) cytotoxicity against kidney cancer in vitro and in vivo.
  • These patients had a median age of 60 years (range, 29-72), had a median performance status of 1 (range, 0-1), and had metastatic sites, including lung, bone, lymph node, and liver.
  • This combination of infusional IL-2 with famotidine is active in metastatic kidney cancer.
  • [MeSH-major] Famotidine / administration & dosage. Immunotherapy / methods. Interleukin-2 / administration & dosage. Kidney Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Drug Synergism. Female. Humans. Killer Cells, Lymphokine-Activated / drug effects. Killer Cells, Lymphokine-Activated / immunology. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FAMOTIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17105423.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 5QZO15J2Z8 / Famotidine
  •  go-up   go-down


12. Quan W Jr, Ramirez M, Taylor C, Vinogradov M, Quan F, Khan N: High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer. Cancer Biother Radiopharm; 2005 Feb;20(1):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose continuous infusion plus pulse interleukin-2 and famotidine in metastatic kidney cancer.
  • High-dose continuous infusion interleukin-2 (IL-2) regimens generate a higher degree of lymphokine activated killer cell (LAK) cytotoxicity when tested against tumor cells in vitro and a higher rebound lymphocytosis in vivo than do bolus IL-2 regimens.
  • Lymphocytes initially activated by continuous infusion IL-2 have increased cytotoxicity against cancer cells when they are subsequently pulsed with additional IL-2.
  • Six patients with kidney cancer have been treated with a combination of famotidine 20 mg intravenous bid and continuous infusion IL-2 (18 MIU/sq m/24 hours) for 72 hours, followed by a 24-hour rest, then IL-2 18 MIU/sq m over 15-30 minutes.
  • The most common metastatic sites were the lung, lymph node, and bone.
  • The combination of high-dose continuous infusion plus pulse IL-2 and famotidine is active in metastatic kidney cancer.
  • [MeSH-major] Famotidine / administration & dosage. Interleukin-2 / administration & dosage. Kidney Neoplasms / drug therapy. Killer Cells, Lymphokine-Activated / cytology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / pharmacology. Combined Modality Therapy. Female. Histamine H2 Antagonists / pharmacology. Humans. Immunotherapy, Adoptive / methods. Male. Middle Aged. Neoplasm Metastasis. Time Factors

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. FAMOTIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778577.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Histamine H2 Antagonists; 0 / Interleukin-2; 5QZO15J2Z8 / Famotidine
  •  go-up   go-down


13. Quan WD Jr, Walker PR, Quan FM, Ramirez M, Elsamaloty HM, Ghai V, Vinogradov M, Liles DK: Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. Cancer Biother Radiopharm; 2006 Oct;21(5):437-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
  • Lymphokine-activated killer (LAK) cells generated by high-dose continuous infusion interleukin-2 (IL-2) are able to nonspecifically lyse melanoma and kidney cancer cells.
  • In vitro famotidine enhances cytotoxicity of LAK against tumor cells, possibly by increasing IL-2 uptake at the IL-2 receptor on lymphocytes.
  • Second-line therapy is, therefore, needed.
  • We treated 11 patients (6 with metastatic melanoma; 5 having metastatic kidney cancer) who had previously experienced progressive disease on prior IL-2 regimens, with a combination of famotidine 20 mg intravenously (i.v.) twice per day and continuous-infusion IL-2 18 MIU/M2/24 hours x 72 hours, followed 24 hours later by a pulse IL-2 dose (18 MIU/M2 over 15 minutes).
  • Patient characteristics were: 9 males, median age 63 years (range, 57-75), median Eastern Cooperative Oncology Group (ECOG) performance status: 1; most common metastatic sites: lungs, lymph nodes, and soft tissue/subcutaneous (s.c.
  • Five (5) patients (3 with melanoma, 2 with kidney cancer) have had partial responses.
  • Two (2) patients with kidney cancer have been converted to complete responders with resection of residual disease, remaining without relapse at 5+ and 20+ months.
  • This combination has activity in patients with metastatic kidney cancer or melanoma who have received prior IL-2.
  • [MeSH-major] Famotidine / administration & dosage. Immunotherapy / methods. Interleukin-2 / administration & dosage. Kidney Neoplasms / therapy. Melanoma / therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Synergism. Female. Humans. Infusions, Intravenous. Killer Cells, Lymphokine-Activated / drug effects. Killer Cells, Lymphokine-Activated / immunology. Male. Middle Aged. Neoplasm Metastasis


14. Ko YJ, Atkins MB: Chemotherapies and immunotherapies for metastatic kidney cancer. Curr Urol Rep; 2005 Feb;6(1):35-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapies and immunotherapies for metastatic kidney cancer.
  • Most patients who develop kidney cancer are effectively treated with a radical nephrectomy; however, for those patients who present with or develop metastatic disease, the therapeutic options are limited.
  • Although cytotoxic chemotherapy continues to have a minor role in patients with clear cell renal carcinoma, it may become the treatment of choice for some patients with variant renal cancers.
  • Novel agents targeting the vascular endothelial growth factor, its receptor, and other hypoxia-induced proteins are showing great promise and soon may expand the therapeutic options for patients with advanced kidney cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / secondary
  • [MeSH-minor] Clinical Trials, Phase III as Topic. Female. Humans. Immunotherapy / methods. Interferons / therapeutic use. Interleukins / therapeutic use. Male. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15610695.001).
  • [ISSN] 1527-2737
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Interleukins; 9008-11-1 / Interferons
  • [Number-of-references] 51
  •  go-up   go-down


15. Albouy B, Billemont B, Massard C, Gross-Goupil M, Rixe O, Escudier B: Pancreatic metastasis from renal cell carcinoma: Presentation, recurrence, survival, and response to antiangiogenic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16137
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis from renal cell carcinoma: Presentation, recurrence, survival, and response to antiangiogenic therapy.
  • : e16137 Background: Pancreas represents an uncommon site of metastasis in renal cell carcinoma (RCC).
  • The natural history of pancreatic metastases is largely unknown, and efficacy of targeted agents has never been assessed.
  • We examined the outcome in a series of RCC patients (pts) with pancreatic metastases, treated by either surgery or antiangiogenic therapy.
  • METHODS: We reviewed the charts of RCC pts treated for pancreatic metastases, between 2001 and 2008, in Institut Gustave Roussy and Pitié-Salpetrière Hospital.
  • Data base was reviewed to determine presentation, clinical symptoms, pancreatic metastases treatment, use of systemic therapy, disease-free survival (DFS) or progression-free survival (PFS) and overall survival (OS) after treatment.
  • RESULTS: A total of 40 pts with pancreatic metastases from RCC have been analyzed.
  • Median age was 63 years (range: 48-81), sex ratio M/F was 29/11, and metastases occurred initially (synchroneous) in 9 pts, while they were metachronous in 31 pts.
  • Most of the metastases were asymptomatic (87%), detected on routine CT scans, while only 12% were symptomatic (pain, cholestasis).
  • Surgical resection of pancreatic metastases was performed in 8 (20%) patients, and DFS and OS were 45 and 66 months.
  • In patients with multiple metastatic sites (lung : 20 (50%); liver : 8 (20%); thyroid : 3(7%)), therapeutic approaches have included antiangiogenic therapies (75%): sorafenib (20 pts), sunitinib (7 pts), bevacizumab (2 pts), Torisel (1 pt).
  • CONCLUSIONS: Patients with RCC pancreatic metastases seem to have a longer survival than the usual metastatic RCC pts.
  • Surgical resection must be discussed in pauci-metastatic disease, as it can be associated with prolonged survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963352.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sahi C, Knox JJ, Hinder V, Deva S, Cole D, Clemons M, Broom RJ: The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16145
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma.
  • : e16145 Background: Bone metastases (BM) from renal cell carcinoma (RCC) are common and associated with poor outcomes.
  • While the multi-tyrosine kinase inhibitors (TKI's) sunitinib and sorafenib have advanced the treatment of metastatic RCC, their efficacy on BM is unknown.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963429.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kwok Y, Patchell RA: Commentary (Kwok/Patchell): Radiation Therapy in the Management of Brain Metastases From Renal Cell Carcinoma. Oncology (Williston Park); 2006 May 01;20(6)
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Commentary (Kwok/Patchell): Radiation Therapy in the Management of Brain Metastases From Renal Cell Carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28326511.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Pollock BE: Commentary (Pollock): Radiation Therapy in the Management of Brain Metastases From Renal Cell Carcinoma. Oncology (Williston Park); 2006 May 01;20(6)
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Commentary (Pollock): Radiation Therapy in the Management of Brain Metastases From Renal Cell Carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28326510.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Brown JE, Lipton A, Cook RJ, Michaelson D, Coleman RE, Saad F: Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):e16016
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC).
  • : e16016 Background: The osteolysis marker NTX has shown prognostic significance in pts with bone metastases from a broad range of solid tumors, but its potential in pts with RCC has not been investigated.
  • J Natl Cancer Inst. 2005).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962910.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Botteman MF, Kaura S: Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases from renal cell carcinoma: Comparison between France, Germany, and the United Kingdom. J Clin Oncol; 2009 May 20;27(15_suppl):5106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases from renal cell carcinoma: Comparison between France, Germany, and the United Kingdom.
  • : 5106 Background: Zoledronic acid (ZOL) significantly reduces the risk of new skeletal-related events (SREs) in patients (pts) with bone metastases from RCC.
  • METHODS: This analysis was based on a retrospective analysis of RCC pts with bone metastases who were enrolled in a 9-mo trial of ZOL or placebo (PBO) plus concomitant antineoplastic therapy.
  • SRE costs were estimated using diagnosis-related group tariff information and published literature.
  • CONCLUSIONS: Treatment with ZOL reduces SREs, improves QOL, and lowers health-related costs compared with PBO in French, German, and UK pts with bone metastases from RCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964368.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Mancuso A, Sternberg CN: New treatments for metastatic kidney cancer. Can J Urol; 2005 Feb;12 Suppl 1:66-70; discussion 105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New treatments for metastatic kidney cancer.
  • Renal cell carcinoma accounts for approximately 3% of adult malignancies and 90%-95% of neoplasms arising from the kidney.
  • International studies have shown objective response rates of < 15% in patients with advanced and metastatic disease, with 5-year disease-specific survival ranging between 0-20%.
  • Considering these poor outcomes, renal cancers' very vascular nature and overexpression of receptors for vascular endothelial growth factor (VEGF), various biologic and angio-suppressive therapies are being evaluated in clinical trials.
  • Promising results in terms of overall response rate and median time to progression have been reported especially as second-line therapy following cytokine failure, a setting where no effective systemic therapy has been recognized (SU011248, Bay 43-9006, Bevacizumab and Erlotinib).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / therapy. Immunotherapy / methods. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Risk Assessment. Sensitivity and Specificity. Survival Analysis. Treatment Outcome


22. Cornu JN, Rouprêt M, Bensalah K, Oudard S, Patard JJ: [Antiangiogenics: new therapeutic standards in metastatic kidney cancer]. Prog Urol; 2008 Jul;18 Suppl 4:S69-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antiangiogenics: new therapeutic standards in metastatic kidney cancer].
  • [Transliterated title] Les anti-angiogéniques: de nouveaux standards thérapeutiques dans le cancer du rein métastatique.
  • Since 2004, the treatment of metastatic renal cell carcinoma is in deep mutation.
  • From 2004, studies of new antiangiogenic molecules, acting on the pVHL-HIF way, VEGF, PDGF or tyrosine-kinase receptors have modified the management of metastatic patients.
  • Antiangiogenic agents improve progression-free survival as shown with sunitinib, in first line treatment, or sorafenib, as second line treatment.
  • The m-TOR inhibitors (Temsirolimus), can be used with a benefit on overall survival in case of poor prognosis renal cell carcinoma or non clear cell carcinoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology
  • [MeSH-minor] Benzenesulfonates / therapeutic use. Humans. Indoles / therapeutic use. Neoplasm Metastasis / drug therapy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / therapeutic use. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706374.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


23. Ferrière JM, Wallerand H, Bernhard JC, Cornu JN, Rouprêt M, Ravaud A: [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies]. Prog Urol; 2008 Jul;18 Suppl 4:S88-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
  • [Transliterated title] Intérêt des anti-angiogéniques dans le cancer du rein localement avancé et métastatique en situation néo-adjuvante: à propos de 2 cas.
  • New antiangiogenic molecules have proven an advantage in term of survival in metastatic renal cell carcinoma.
  • We describe herein two clinical cases showing the efficacy of antiangiogenic agent in locally advanced or metastatic renal cell carcinoma.
  • In this cases the surgical management has been altered in front of an important tumor necrosis provided by this treatment.
  • The role of antiangiogenic agents as adjuvant or neo adjuvant therapy has not yet been defined precisely.
  • However, these new molecules open new perspectives in the therapeutic field of metastatic renal cell carcinoma notably in case of bulky tumors which appeared difficult to remove surgically at first look or in case of early recurrence after radical nephrectomy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706377.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  •  go-up   go-down


24. Herrmann E, Gerss J, Bierer S, Köpke T, Bolenz C, Hertle L, Wülfing C: Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib. J Cancer Res Clin Oncol; 2009 Jan;135(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
  • PURPOSE: Our goal was to prospectively evaluate self-reported quality-of-life (QoL) during second-line therapy in 51 consecutive patients with cytokine-refractory kidney cancer treated with sorafenib or sunitinib.
  • CONCLUSIONS: Second-line therapy with sorafenib or sunitinib does not adversely affect patients global QoL after 16 weeks of treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / mortality. Indoles / therapeutic use. Kidney Neoplasms / mortality. Pyridines / therapeutic use. Pyrroles / therapeutic use. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Health Surveys. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Niacinamide / analogs & derivatives. Palliative Care. Phenylurea Compounds. Prognosis. Prospective Studies. Salvage Therapy. Surveys and Questionnaires. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592270.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


25. Dogan M, Ozal G, Ekinci C, Utkan G, Urun Y, Yalcin B, Icli F: Two cases with atypical metastasis in colorectal cancer: splenic and renal metastasis. Exp Oncol; 2010 Dec;32(4):277-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases with atypical metastasis in colorectal cancer: splenic and renal metastasis.
  • Atypical metastasis, such as splenic and renal metastasis is rare in colorectal cancer.
  • There have been case reports of colorectal cancer patients with isolated splenic metastasis, even after years of surgery in the literature.
  • AIM: To report two colorectal cancer cases with atypical metastasis.
  • RESULTS: The first patient was a 58-year old man who had isolated splenic metastasis after 20 months of surgery.
  • The other one was a 51-year old male patient with both lung and renal metastasis at rectal cancer diagnosis.
  • Splenic and renal metastases have been histopathologically documented in both of them.
  • The other one had also multiple lung metastases besides renal metastasis.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Kidney Neoplasms / secondary. Splenic Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Digestive System Surgical Procedures. Humans. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Middle Aged. Palliative Care


26. Siebels M, Staehler M, Hegele A, Varga Z, Oberneder R, Doehn C, Heinzer H, Deutsche Gesellschaft für Immun- und Targeted Therapie e.V. (DGFIT): [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)]. Aktuelle Urol; 2010 Mar;41(2):122-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
  • [Transliterated title] Welche Bedeutung hat die Immuntherapie beim metastasierten Nierenzell-karzinom nach Einführung der neuen Target-Substanzen in Deutschland--Ergebnisse einer repräsentativen Umfrage der DGFIT.
  • INTRODUCTION: Until recently, the standard therapy for metastatic renal cell carcinoma (mRCC) in Germany consisted of interleukin-2 (IL-2), interferon-alfa (IFN) as single agents or in combination, with or without chemotherapy.
  • 98% of patients with mRCC were treated: A: the most frequent therapy was sunitinib (43%, 42%, 33% as first-, second-, third-line), B: the most frequent therapy was sunitinib (45% as first-line, 37% as second-line), the most frequent third-line therapy was sorafenib (35%); C: the most frequent therapy were sorafenib and sunitinib (first-line 26% vs. 27%, second-line 46% vs. 42%), in third-line therapy additionally temsirolimus 24%; D: primary sorafenib and sunitinib (first-line 33% vs. 40%, second-line 46% vs. 42%), in third-line therapy additionally temsirolimus 23%.
  • Immunotherapy (IL-2, IFN with or without chemotherapy) in mRCC plays in Germany for the second- and third-line therapy in A-D no major role (less than 10%).
  • Sunitinib (in first-line) and sorafenib (in second-line) are currently the most frequent prescribed drugs in mRCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Drug Delivery Systems / methods. Immunotherapy / methods. Indoles / therapeutic use. Kidney Neoplasms / drug therapy. Pyridines / therapeutic use. Pyrroles / therapeutic use. Sirolimus / analogs & derivatives

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart New York.
  • (PMID = 19937556.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Interferon-alpha; 0 / Interleukin-2; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 624KN6GM2T / temsirolimus; 9ZOQ3TZI87 / sorafenib; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


27. Malhotra G, Upadhye TS, Sridhar E, Asopa RV, Garde PS, Gawde S, Rangarajan V: Unusual case of adrenal and renal metastases from papillary carcinoma of thyroid. Clin Nucl Med; 2010 Sep;35(9):731-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual case of adrenal and renal metastases from papillary carcinoma of thyroid.
  • We report a rare case of adrenal and renal metastases from papillary thyroid carcinoma (PTC).
  • A 30-year-old man underwent total thyroidectomy with left neck dissection for cytology proven nodal metastases from PTC.
  • Magnetic resonance imaging examination of spine detected left SI joint, dorsal and lumbar vertebral metastases.
  • Contrast-enhanced CT of abdomen revealed lesions in bilateral adrenals and renal regions suggestive of metastases.
  • A CT-guided biopsy of left adrenal focus confirmed metastasis from the carcinoma of thyroid.
  • A high degree of suspicion with further radiologic and cytologic correlation clinched the diagnosis of both adrenal and renal metastases from PTC, which has been rarely reported.
  • Fortunately, radioiodine concentration in adrenal metastases made them amenable to high-dose radioiodine therapy.
  • This case is a strong reminder of the fact that regular and long-term follow-up is imperative in the management of thyroid cancer patients.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Carcinoma, Papillary / pathology. Kidney Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706057.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Iodine Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


28. Sindoni A, Rizzo M, Tuccari G, Ieni A, Barresi V, Calbo L, Cucinotta E, Trimarchi F, Benvenga S: Thyroid metastases from renal cell carcinoma: review of the literature. ScientificWorldJournal; 2010;10:590-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid metastases from renal cell carcinoma: review of the literature.
  • The thyroid gland is a rare site of clinically detectable tumor metastasis and kidneys are frequently the site of the parent malignancy.
  • In the present review on thyroid metastases from renal cell carcinoma, cases were searched on PubMed by entering the strings: "renal carcinoma [or "hypernephroma"] AND thyroid metastasis/metastases".
  • The primary renal cancer was almost always unilateral (90%) (with no significant side preference) and only rarely bilateral (9% in men, 4% in women), whereas bilaterality of thyroid metastases was relatively more frequent (28%).
  • Thyroid metastasis from renal cancer was commonly single with a unique node that appears solid and hypoechoic at ultrasonography, approximately 9 years after nephrectomy.
  • Concordance of lateralization was insignificantly greater for the right kidney/right thyroid lobe pattern (54%) than for the left kidney/left thyroid lobe pattern (40%), regardless of gender.
  • Thyroid metastases, even if rare in the clinical practice, must be considered in the differential diagnosis of a thyroid nodule, particularly in patients who have a history of malignancies.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Thyroid Neoplasms / secondary


29. Hallock A, Rodrigues G: Toothache as a presenting symptom of metastatic renal cell cancer. Can Urol Assoc J; 2009 Oct;3(5):E42-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toothache as a presenting symptom of metastatic renal cell cancer.
  • A 53-year-old man with a 14-year history of renal cell carcinoma (RCC) presented with a 2-month history of right-sided upper jaw pain and severe bleeding during tooth extraction.
  • Pathology review of a lower maxillary sinus/upper gingival mass revealed metastatic RCC.
  • The presentation, differential diagnosis and literature review of this uncommon presentation of metastatic kidney cancer are discussed in this report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Apr;132(4):663-4 [15806067.001]
  • [Cites] Acta Otolaryngol Suppl. 1998;537:82-6 [9870654.001]
  • [Cites] Br J Oral Maxillofac Surg. 2003 Feb;41(1):3-6 [12576032.001]
  • [Cites] Urol Int. 1987;42(4):316-7 [3672663.001]
  • [Cites] Int J Oral Maxillofac Surg. 1990 Apr;19(2):106-9 [1692867.001]
  • [Cites] Scand J Urol Nephrol. 1998 May;32(3):239-40 [9689710.001]
  • (PMID = 19829716.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2759659
  •  go-up   go-down


30. Hassaneen W, Hatiboglu MA, Chowdhury S, Sawaya R: Asymptomatic cerebellopontine angle and lateral ventricle metastases from renal cell carcinoma: case report and literature review. J Neurooncol; 2009 Jan;91(1):101-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic cerebellopontine angle and lateral ventricle metastases from renal cell carcinoma: case report and literature review.
  • We report the first instance of simultaneous metastasis of renal cell carcinoma to the cerebellopontine angle and the lateral ventricle.
  • A 51-year-old man presented with anemia and fatigue owing to stomach metastases from renal cell carcinoma 8 years after undergoing partial left nephrectomy for grade II clear cell renal carcinoma and radical right nephrectomy for grade III clear cell renal carcinoma.
  • He also suffered metastases to the lung, both adrenal glands, the L-3 vertebra, and the brain (asymptomatic, but revealed by magnetic resonance imaging): a 1-cm (maximum diameter) mass in the left medullary cistern and a 2-cm (maximum diameter) mass in the right lateral ventricle trigone.
  • Both tumors shrank significantly, but the patient died from progressive systemic cancer 1 year after diagnosis of brain metastasis.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Renal Cell / pathology. Cerebellopontine Angle / pathology. Kidney Neoplasms / pathology. Lateral Ventricles / pathology


31. Liou MJ, Lin JD, Chung MH, Liau CT, Hsueh C: Renal metastasis from papillary thyroid microcarcinoma. Acta Otolaryngol; 2005 Apr;125(4):438-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal metastasis from papillary thyroid microcarcinoma.
  • Distant metastasis caused by thyroid microcarcinoma is uncommon, and is usually found in the lung or bone.
  • Thyroid microcarcinoma with metastasis to the kidney has not previously been reported.
  • Clinically detectable well-differentiated metastatic thyroid carcinoma to the kidney is rare, and only 16 cases have been reported.
  • Herein we describe a case of metastatic papillary thyroid microcarcinoma to the kidney in a patient with a pelvic fracture and pulmonary metastasis.
  • Although uncommon, metastases may arise.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Papillary / secondary. Kidney Neoplasms / secondary. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Calcinosis / diagnosis. Calcinosis / pathology. Disease Progression. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Middle Aged. Pelvic Bones / pathology. Thyroglobulin / blood. Thyroid Gland / pathology. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823819.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


32. Romain B, Schneider M, Jung JL, Detloff H, Krzisch S, Chartier-Kastler E: [Renal metastasis of an esophagus epidermoid carcinoma]. Prog Urol; 2009 May;19(5):348-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal metastasis of an esophagus epidermoid carcinoma].
  • [Transliterated title] Métastase rénale d'un carcinome épidermoïde de l'oesophage.
  • Renal metastases in the evolution of an esophagus epidermoid carcinoma are rare and are frequently bilateral or associated with many other metastases.
  • The authors present an original article of a single metastasis.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Kidney Neoplasms / secondary

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19393541.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


33. Phé V, Rouprêt M, Lechevallier E, Patard JJ: [What's new in 2008 in kidney cancer?]. Prog Urol; 2009 May;19 Suppl 2:S56-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [What's new in 2008 in kidney cancer?].
  • [Transliterated title] Quelles nouveautes en 2008 dans le cancer du rein ?
  • The most innovating studies presented at the 2008 international conferences in the field of kidney cancer were selected.
  • In localized kidney cancer, contrast-enhanced ultrasonography could be a new diagnostic tool.
  • Many communications dealed with positive surgical margins and their consequences, and predictive factors of chronic kidney disease after nephrectomy.
  • In metastatic kidney cancer, sunitinib was compared to IFN-alpha in first line treatment and survival data are now available.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Neoplasm Metastasis. Neoplasm Recurrence, Local. Nephrectomy / methods

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19447330.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


34. Giigoruk OG, Lazarev AF, Doroshenko VS: [Pleural metastases of renal carcinoma]. Urologiia; 2007 Mar-Apr;(2):42-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural metastases of renal carcinoma].
  • Metastases in renal carcinoma are diagnosed at initial diagnosis in 25% examinees.
  • Traditional renal carcinoma has higher metastatic potential, is associated with worse survival of the patients compared to papillary cancer.
  • We studied cytological characteristics of renal carcinoma metastases to the pleura in comparison with histological studies of the primary lesion using immunohistochemical findings.
  • We examined cytologically pleural liquid in renal carcinoma metastases to the pleura in 6 patients (2.3% of carcinomatous pleuricies).
  • In 3 cases initial cancer was renal cell carcinoma, pleural exudation developed 2 years later, clear cell carcinoma appeared 6 years later and papillary cancer--10 years later.
  • In the other 3 cases malignant cells were detected in new-onset cases.
  • Renal carcinoma was diagnosed in one case.
  • Cytological preparations were studied with identification of cytological signs typical for classic clear cell, granulocell and papillary renal cancer.
  • Immunohistochemical examination of primary tumor lesion in the kidney discovered high proliferative activity of tumor cells by Ki-67 index to 5.28%.
  • This is confirmed by renal carcinoma metastases to the pleura.
  • [MeSH-major] Carcinoma / secondary. Kidney Neoplasms / pathology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / analysis. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578198.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


35. Alexandrescu DT, Dasanu CA: Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother; 2006 Dec;7(18):2481-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney cancer therapy: new perspectives and avenues.
  • Immunotherapy with interleukin-2 and interferon-alpha has been the only viable option in metastatic renal cell cancer for almost two decades.
  • In the last several years, significant advances in the understanding of the underlying biological and molecular mechanisms of renal cell carcinoma, particularly the role of tumour angiogenesis, have led to the identification of rational therapeutic targets and permitted the design of molecularly targeted therapeutics.
  • The use of small molecules, such as multitargeted tyrosine kinase inhibitors, the mTOR inhibitors and monoclonal antibodies, is dramatically changing the existing concepts of systemic treatment for metastatic kidney cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / drug therapy. Drug Delivery Systems / trends. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17150003.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 86
  •  go-up   go-down


36. Fokt RM, Templeton A, Gillessen S, Ohlschlegel C, Schmid HP: Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. Urol Int; 2009;83(1):122-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.
  • Metastases of renal cell carcinoma to the prostate gland are very rare.
  • We present a case of a metastasis of renal cell carcinoma in the prostate which occurred 10 years after nephrectomy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / secondary. Indoles / therapeutic use. Kidney Neoplasms / pathology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / secondary. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19641373.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  • [Number-of-references] 14
  •  go-up   go-down


37. Köhler K, Haroske G, Ludwig K: [Management of pancreatic metastases from renal cell carcinoma report of five cases]. Zentralbl Chir; 2006 Oct;131(5):425-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of pancreatic metastases from renal cell carcinoma report of five cases].
  • Pancreatic metastases from renal cell carcinoma are rare.
  • In most cases metastases occur many years after nephrectomy.
  • Solitary pancreatic metastases of renal cell cancer can be the only manifestation of tumor dissemination.
  • Between 1995 and 2005 five patients after nephrectomy due to renal cell cancer were suspected of having malignant pancreatic tumor and underwent an operation.
  • The histology revealed metastases of renal cancer.
  • The intervals from primary renal tumor resection to recognition of metastases in the pancreas varied from 6-17 years.
  • The prognosis of metastatic invasion to the pancreas is better than that of primary pancreatic carcinoma.
  • Radical resection of the tumor is the treatment of choice for isolated solitary late metastases of renal cell cancer in the pancreas.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lymph Node Excision. Magnetic Resonance Imaging. Middle Aged. Nephrectomy. Pancreatectomy. Pancreaticoduodenectomy. Prognosis. Splenectomy. Thyroid Neoplasms / secondary. Thyroid Neoplasms / surgery. Thyroidectomy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome


38. Thelen A, Jonas S, Benckert C, Lopez-Hänninen E, Rudolph B, Neumann U, Neuhaus P: Liver resection for metastases from renal cell carcinoma. World J Surg; 2007 Apr;31(4):802-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for metastases from renal cell carcinoma.
  • BACKGROUND: This study was conducted to evaluate the safety and efficacy of liver resection in patients with hepatic metastases from renal cell carcinoma and to identify selection criteria for patients suitable for resection.
  • METHODS: Between January 1988 and March 2006, 31 patients underwent liver resection for metastases from renal cell carcinoma.
  • Patient, tumor, and operative parameters were analyzed for their influence on long-term survival.
  • In the univariate analysis, site of the primary tumor (P = 0.013), disease-free interval (P = 0.012), and resection margins (P = 0.008) showed significant influence on long-term survival.
  • CONCLUSIONS: Liver resection is effective and safe in the treatment of patients with hepatic metastases from renal cell carcinoma and offers the chance of long-term survival and cure.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Hepatectomy / methods. Kidney Neoplasms / pathology. Liver Neoplasms / surgery


39. Mulamalla K, Truskinovsky AM, Dudek AZ: Pulmonary blastoma with renal metastasis responds to sorafenib. J Thorac Oncol; 2007 Apr;2(4):344-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary blastoma with renal metastasis responds to sorafenib.
  • Biphasic pulmonary blastoma is a rare malignancy of the lung composed of proliferating epithelial and mesenchymal cells with a high vessel density at the tumor periphery.
  • We report a rare case of renal metastasis of biphasic pulmonary blastoma that responded to sorafenib, an oral multikinase inhibitor.
  • After 2 months of treatment with sorafenib, the renal tumor size decreased sufficiently to allow a safe laparoscopic radical nephrectomy.
  • [MeSH-major] Benzenesulfonates / administration & dosage. Kidney Neoplasms / drug therapy. Kidney Neoplasms / secondary. Lung Neoplasms / pathology. Pulmonary Blastoma / secondary. Pyridines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Nephrectomy / methods. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pneumonectomy / methods. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Blastoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409808.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


40. Sibaud V, Delord JP, Chevreau C: Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon? Target Oncol; 2009 Dec;4(4):307-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sorafenib is a tyrosine kinase inhibitor prescribed primarily for the management of metastatic kidney cancer.
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Humans. Kidney Neoplasms / drug therapy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Prognosis. Skin Diseases / chemically induced. Skin Tests

  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894099.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


41. Dasanu CA, Alexandrescu DT, Dutcher J: Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma. South Med J; 2007 Mar;100(3):328-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
  • This report describes a patient with metastatic kidney cancer who developed a deep yellow skin discoloration while on therapy with the oral multitargeted tyrosine kinase inhibitor (TKI), sorafenib.
  • A thorough clinicolaboratory investigation did not reveal any evidence of jaundice, B12 deficiency, anemia, carotenemia, hypothyroidism, or any other disorder of endocrine or metabolic etiology.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Benzenesulfonates / adverse effects. Carcinoma, Renal Cell / secondary. Pigmentation Disorders / chemically induced. Protein Kinase Inhibitors / adverse effects. Pyridines / adverse effects. raf Kinases / antagonists & inhibitors
  • [MeSH-minor] Acrodermatitis / chemically induced. Erythema / chemically induced. Humans. Kidney Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Spinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] South Med J. 2007 May;100(5):485
  • (PMID = 17396743.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.1 / raf Kinases
  •  go-up   go-down


42. Mottet N: [Role of nephrectomy in metastatic renal cell carcinoma]. Ann Urol (Paris); 2006 Oct;40(5):273-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of nephrectomy in metastatic renal cell carcinoma].
  • [Transliterated title] Place de la néphrectomie dans la prise en charge des cancers du rein métastatiques.
  • Metastatic kidney cancer is still a devastating disease but it represents a very heterogeneous situation.
  • If the initial diagnosis of kidney cancer at metastatic stage is quite uncommon, it raises the question of whether or not performing initial nephrectomy.
  • Furthermore spontaneous postoperative metastasis regression is unusual.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Nephrectomy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100164.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 41
  •  go-up   go-down


43. Kirkali Z: Kidney cancer in the elderly. Urol Oncol; 2009 Nov-Dec;27(6):673-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney cancer in the elderly.
  • Kidney cancer in the elderly patient is a real challenge for the oncologic urologist.
  • With the aging population, we will face more patients with renal cell carcinoma in senior adults.
  • There is evidence that elderly patients with RCC have more aggressive disease and lower cancer-specific survival.
  • Elderly patients with metastatic kidney cancer can benefit from systemic therapy; however, they should be closely monitored for serious adverse events.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy. Urologic Surgical Procedures

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19879478.001).
  • [ISSN] 1873-2496
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


44. Ploussard G, de La Taille A: [What is the importance of kidney cancer surgery in contrast with targeted therapies?]. Bull Cancer; 2010;97:91-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [What is the importance of kidney cancer surgery in contrast with targeted therapies?].
  • [Transliterated title] Chirurgie du cancer du rein : quelle place à l'ère des thérapies ciblées ?
  • Despite the extraordinary development of the medical treatment of kidney cancer, its treatment remains very surgical in localized and metastatic stage.
  • Partial nephrectomy for tumors between 4 and 7 cm is feasible for selected patients with favorable tumor localization.
  • In the future, the use of neo-adjuvant anti-angiogenesis agents could broaden the scope of partial nephrectomy.
  • In case of metastatic disease, pending the results of randomized trials including patients on anti-angiogenesis agents, cytoreductive nephrectomy remains indicated for patients in good general condition with kidney cancer metastatic immediately.
  • [MeSH-major] Kidney Neoplasms / surgery. Laparoscopy / methods. Nephrectomy / methods

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418208.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors
  •  go-up   go-down


45. Ho L, Wassef H, Henderson R, Seto J: Renal metastasis from primary colon cancer on FDG PET-CT. Clin Nucl Med; 2009 Sep;34(9):596-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal metastasis from primary colon cancer on FDG PET-CT.
  • We report the PET-CT appearance of a metastasis from a primary colon cancer to the right kidney in an 84-year-old woman with a history of moderately differentiated adenocarcinoma of the cecum.
  • Restaging PET-CT study, 4 months after her last chemotherapy, demonstrates a hypermetabolic soft-tissue mass in the inferior pole of the right kidney.
  • The pathology was consistent with metastatic colonic adenocarcinoma.
  • Renal metastasis from primary colon cancer is very rare.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Kidney Neoplasms / radionuclide imaging. Kidney Neoplasms / secondary

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692821.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


46. Sotiropoulos GC, Lang H, Liu C, Brokalaki EI, Molmenti E, Broelsch CE: Surgical treatment of pancreatic metastases of renal cell carcinoma. JOP; 2005 Jul;6(4):339-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of pancreatic metastases of renal cell carcinoma.
  • CONTEXT: The pancreas is an unusual site for metastases of renal cell carcinoma origin, sometimes occurring many years after nephrectomy.
  • We herein present two cases of pancreatic metastases of renal cell carcinoma which occurred 17 and 19 years after the primary diagnosis.
  • CASE REPORT: In the first case, metastases were found in the head of the pancreas, upper right arm and the right lobe of the thyroid gland.
  • In the second case, a tumor was found in the tail of the pancreas and a remnant of the right kidney.
  • This was the third recurrence of the original tumor after an initial left nephrectomy and two subsequent partial right nephrectomies in the past.
  • Treatment in the first case consisted of excision of the tumor in the upper right arm, a Whipple operation, and a thyroidectomy.
  • In the second case, a distal pancreatectomy and remnant right nephrectomy were undertaken.
  • Both patients recovered from the operations without complications and remain free of tumor in follow-up periods of 54 and 8 months respectively.
  • CONCLUSIONS: Resection of renal cell carcinoma metastases involving the pancreas provides satisfactory long-term survival, and should be undertaken whenever possible.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery


47. García Torrelles M, Beltrán Armada JR, Verges Prosper A, Santolaya García JI, Espinosa Ruiz JJ, Tarín Planes M, Sanjuán de Laorden C: [Cutaneous metastases of renal cell carcinoma]. Actas Urol Esp; 2007 May;31(5):556-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous metastases of renal cell carcinoma].
  • [Transliterated title] Metastasis cutánea de carcinoma de células renales.
  • Renal cell carcinoma has an unknown evolution.
  • We report a case of a man with a skin metastases from renal cell carcinoma and an unfortunate result, five years after its radical surgical treatment.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Head and Neck Neoplasms / secondary. Kidney Neoplasms / pathology. Scalp. Skin Neoplasms / secondary


48. Cooney MM, Remick SC, Vogelzang NJ: Promising systemic therapy for renal cell carcinoma. Curr Treat Options Oncol; 2005 Sep;6(5):357-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promising systemic therapy for renal cell carcinoma.
  • In the United States, advanced kidney cancer accounts for over 12,000 deaths each year.
  • Interferon typically results in very few long-term responses and is given to most patients with metastatic kidney cancer.
  • Novel compounds currently being tested in clinical trials are showing promise in advanced kidney cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Ixabepilone .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16107239.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Epothilones; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / Quinazolines; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 4Z8R6ORS6L / Thalidomide; 9ZOQ3TZI87 / sorafenib; DA87705X9K / Erlotinib Hydrochloride; F0P408N6V4 / lenalidomide; K27005NP0A / ixabepilone
  • [Number-of-references] 44
  •  go-up   go-down


49. Rosner I, Bratslavsky G, Pinto PA, Linehan WM: The clinical implications of the genetics of renal cell carcinoma. Urol Oncol; 2009 Mar-Apr;27(2):131-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical implications of the genetics of renal cell carcinoma.
  • Over the last several decades, the advances in molecular genetics have elucidated kidney cancer gene pathways.
  • Kidney cancer is a heterogeneous disorder.
  • Each specific type of kidney cancer has its own histologic features, gene, and clinical course.
  • Insight into the genetic basis of kidney cancer has been learned largely from the study of the familial or hereditary forms of kidney cancer.
  • Extirpative surgery is currently the treatment of choice for kidney cancer that is confined to the kidney.
  • Treatment for advanced or metastatic kidney cancer is a formidable challenge with the traditional therapies currently available.
  • However, investigation of the Mendelian single-gene syndromes, like von Hippel Lindau (VHL: VHL gene), hereditary papillary renal carcinoma (HPRC: c-Met gene), Birt-Hogg-Dubé (BHD: BHD gene), and hereditary leiomyomatosis renal cell cancer (HLRCC: fumarate hydratase gene) provides an opportunity to develop pathway specific therapies.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / genetics. Kidney Neoplasms / therapy. Medical Oncology / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1719-22 [9563489.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):737-41 [9294565.001]
  • [Cites] Hum Mutat. 1998;12(6):417-23 [9829911.001]
  • [Cites] J Urol. 1999 May;161(5):1475-9 [10210376.001]
  • [Cites] JAMA. 1999 May 5;281(17):1628-31 [10235157.001]
  • [Cites] Am J Hum Genet. 2005 Jun;76(6):1023-33 [15852235.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):931-5 [15956655.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):143-53 [16098467.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2505-12 [16636341.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Hum Mutat. 2007 Feb;28(2):143-9 [17024664.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):403-7 [17211469.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1578-85 [17895761.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):66-9 [9731534.001]
  • [Cites] Nat Genet. 1997 May;16(1):68-73 [9140397.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2156-61 [9122164.001]
  • [Cites] Kidney Int. 1997 Jan;51(1):16-26 [8995713.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10595-9 [8855223.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3387-92 [11248088.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):876-82 [11533913.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):406-10 [11865300.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):393-400 [11927500.001]
  • [Cites] Int J Urol. 2002 Jan;9(1):19-23 [11972645.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] J Urol. 2002 Dec;168(6):2411-2 [12441928.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] J Cell Biochem. 2003 Feb 1;88(2):408-17 [12520544.001]
  • [Cites] Am J Hum Genet. 2003 Jul;73(1):95-106 [12772087.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3127-32 [12915604.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] Hum Mutat. 2004 Jan;23(1):40-6 [14695531.001]
  • [Cites] J Urol. 2004 Jul;172(1):63-5 [15201738.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):7-10 [15261137.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1256-61 [15371818.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):223-8 [15380513.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6282S-9S [15448018.001]
  • [Cites] Annu Rev Genet. 1986;20:231-51 [2880556.001]
  • [Cites] Nature. 1987 Jun 25-Jul 1;327(6124):721-4 [2885753.001]
  • [Cites] J Natl Cancer Inst. 1989 Jul 19;81(14):1097-101 [2738940.001]
  • [Cites] Science. 1991 Feb 15;251(4995):802-4 [1846706.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Jul;3(4):256-62 [1958591.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] J Urol. 1994 Mar;151(3):561-6 [8308957.001]
  • [Cites] Adv Cancer Res. 1993;62:89-124 [8109322.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2852-5 [8187067.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] Hum Mutat. 1995;5(1):66-75 [7728151.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1402-6 [7660122.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1444-6 [7660130.001]
  • [Cites] J Urol. 1995 Dec;154(6):2010-4; discussion 2014-5 [7500446.001]
  • (PMID = 19285230.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC006659-25
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  • [Other-IDs] NLM/ NIHMS108859; NLM/ PMC2686112
  •  go-up   go-down


50. Feiz-Erfan I, Rhines LD, Weinberg JS: The role of surgery in the management of metastatic spinal tumors. Semin Oncol; 2008 Apr;35(2):108-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surgery in the management of metastatic spinal tumors.
  • The role of surgery in the treatment of metastatic spinal tumors causing epidural compression traditionally consisted of posterior decompression.
  • This procedure plus radiotherapy, however, could not be demonstrated to provide any benefit over radiotherapy alone, and surgery fell into disfavor in managing metastatic vertebral tumors.
  • The advent of newer, more sophisticated approaches, along with improved spinal instrumentation and reconstruction techniques, which allowed direct decompression of neural elements and resection of the tumor, have revived the use of surgery in these tumors.
  • These modern spinal surgery techniques, in combination with radiotherapy, have yielded significantly superior functional outcomes and prolonged survival in symptomatic metastatic epidural compression when compared to radiotherapy alone.
  • Management of spinal metastases is evolving, and a multitude of factors determine the indication for and the technique and goals of surgical intervention.
  • Between 1993 and 2005, 21.1% of patients with metastatic spinal tumors evaluated at The University of Texas M.D.
  • Anderson Cancer Center were treated surgically by the Department of Neurosurgery.
  • The most common spinal metastasis operated upon was metastatic kidney cancer (31.5%), even though kidney cancer was only the third most common primary tumor (after lung and breast cancers) giving rise to vertebral metastases observed during the same time period at this institution.
  • This highlights the importance of the histology of the primary cancer (among other factors) in determining the indication for surgical intervention.
  • [MeSH-major] Spinal Neoplasms / secondary. Spinal Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396196.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 110
  •  go-up   go-down


51. Koutras AK, Krikelis D, Alexandrou N, Starakis I, Kalofonos HP: Brain metastasis in renal cell cancer responding to sunitinib. Anticancer Res; 2007 Nov-Dec;27(6C):4255-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis in renal cell cancer responding to sunitinib.
  • BACKGROUND: Sunitinib (SU011248; Sutent) is a new small molecule that inhibits members of the split-kinase domain family of receptor tyrosine kinases (RTKs), with established antitumor activity in renal cancer.
  • In the current report, we describe a patient with a solitary brain metastasis from renal cell carcinoma who achieved partial response of the cerebral lesion following treatment with sunitinib.
  • To the best of our knowledge, this is the first report of sunitinib activity in brain metastases from kidney cancer.
  • Although the role of sunitinib in advanced renal carcinoma has been evaluated through prospective trials, the efficacy of the drug in patients with brain metastases has not been explored, since patients with cerebral lesions were excluded in those studies.
  • Moreover, in our case, sunitinib was found to be safe, leading to considerable shrinkage of the brain metastasis without any serious adverse events or central nervous system toxicities.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Indoles / therapeutic use. Kidney Neoplasms / pathology. Pyrroles / therapeutic use


52. Jost G, Zimmerer S, Frank S, Cordier D, Merlo A: Intradural spinal metastasis of renal cell cancer. Report of a case and review of 26 published cases. Acta Neurochir (Wien); 2009 Jul;151(7):815-21; discussion 821
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intradural spinal metastasis of renal cell cancer. Report of a case and review of 26 published cases.
  • Metastatic disease in the intradural compartment of the spine is a rare manifestation of cancer.
  • We report the case of an 82-year-old patient with an intradural, extramedullary metastasis of renal cell carcinoma in the cervical spine.
  • A literature search for intradural spinal metastases of renal cell carcinoma yielded a total of 26 further cases.
  • 18 patients had sporadic renal cell carcinoma, and 9 patients had von Hippel-Lindau disease (VHL) in which the metastases of the renal cell carcinoma were embedded within spinal haemangioblastomas.
  • Intradural spinal metastases were diagnosed at an earlier age in VHL patients than in sporadic cases (mean 43 +/- 5 years vs. 60 +/- 14.5 years).
  • The metastasis was surgically removed in 81% of patients.
  • Death occurred as a result of systemic cancer progression.
  • 93% of patients in the sporadic renal cell cancer group died within 1.5 years, whereas two thirds of the VHL patients were alive after 2 years.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Neoplasm Metastasis / pathology. Spinal Cord / pathology. Spinal Cord Compression / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Back Pain / etiology. Female. Hemangioblastoma / secondary. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures / methods. Paraparesis / etiology. Secondary Prevention. Subdural Space / pathology. Subdural Space / physiopathology. Subdural Space / surgery. Survival Rate. Urinary Bladder, Neurogenic / etiology. von Hippel-Lindau Disease / complications

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415167.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 46
  •  go-up   go-down


53. Muacevic A, Siebels M, Tonn JC, Wowra B: Treatment of brain metastases in renal cell carcinoma: radiotherapy, radiosurgery, or surgery? World J Urol; 2005 Jul;23(3):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of brain metastases in renal cell carcinoma: radiotherapy, radiosurgery, or surgery?
  • Metastases from renal cell carcinoma raise specific therapeutic problems because they are relatively unresponsive to whole brain radiation therapy and tend to bleed.
  • Recently, stereotactically guided high-precision irradiation as a single dose application (radiosurgery) showed promising treatment results for selected patients with brain metastases from renal cell carcinoma.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Carcinoma, Renal Cell / radiotherapy. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791468.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


54. Singer EA, Bratslavsky G, Linehan WM, Srinivasan R: Targeted therapies for non-clear renal cell carcinoma. Target Oncol; 2010 Jun;5(2):119-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies for non-clear renal cell carcinoma.
  • The treatment of advanced and metastatic kidney cancer has been revolutionized by the development of targeted systemic therapies.
  • Despite the growing number of available agents approved for use against clear cell renal cell carcinoma, patients with non-clear histologies, constituting approximately 1 in 4 cases of kidney cancer, have not received the same attention.
  • This review will focus on the use of targeted therapies against the non-clear histologic subtypes of renal cell carcinoma: papillary I and II, chromophobe, and collecting duct.
  • The unique genetic and molecular profiles of each distinct non-clear kidney cancer subtype will be described, as these differences are integral to the development and effectiveness of the novel agents used to treat them.
  • Trials focusing on non-clear kidney cancer, or those that treated clear cell tumors along with significant numbers of non-clear subtypes, will be discussed.
  • [MeSH-major] Carcinoma, Papillary / therapy. Carcinoma, Renal Cell / therapy. Clinical Trials as Topic. Kidney Neoplasms / therapy

  • Genetic Alliance. consumer health - Clear Cell Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Sep;144(3):614-7; discussion 617-8 [2201792.001]
  • [Cites] J Urol. 1992 Jan;147(1):24-30 [1729540.001]
  • [Cites] Science. 1993 May 28;260(5112):1317-20 [8493574.001]
  • [Cites] Urol Clin North Am. 1993 May;20(2):303-21 [8493752.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):907-12 [7853572.001]
  • [Cites] Nat Genet. 1997 May;16(1):68-73 [9140397.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] Oncogene. 1998 Aug 13;17(6):733-9 [9715275.001]
  • [Cites] J Urol. 1999 Jul;162(1):43-5 [10379736.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2477-90 [16339096.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] J Korean Med Sci. 2006 Aug;21(4):672-7 [16891811.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):517-26 [10433944.001]
  • [Cites] Curr Mol Med. 2004 Dec;4(8):855-68 [15579033.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):591-8 [15659506.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):843-6 [15756254.001]
  • [Cites] Oncologist. 2005 Mar;10(3):191-7 [15793222.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2763-71 [15837991.001]
  • [Cites] Am J Hum Genet. 2005 Jun;76(6):1023-33 [15852235.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):931-5 [15956655.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):143-53 [16098467.001]
  • [Cites] Semin Oncol. 2006 Oct;33(5):544-51 [17045083.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):671s-679s [17255292.001]
  • [Cites] J Urol. 2007 May;177(5):1698-702 [17437788.001]
  • [Cites] J Urol. 2007 Jun;177(6):1978-84 [17509276.001]
  • [Cites] Cancer Treat Rev. 2007 May;33(3):299-313 [17329029.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4667-71 [17699843.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1578-85 [17895761.001]
  • [Cites] J Urol. 2007 Nov;178(5):1896-900 [17868729.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):127-31 [18165647.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1480-8 [18240184.001]
  • [Cites] Expert Opin Biol Ther. 2008 Jun;8(6):779-90 [18476789.001]
  • [Cites] J Urol. 2008 Jul;180(1):94-8 [18485389.001]
  • [Cites] Curr Opin Urol. 2008 Sep;18(5):474-80 [18670270.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1324-31 [18661529.001]
  • [Cites] BJU Int. 2008 Sep;102(6):692-6 [18410444.001]
  • [Cites] BJU Int. 2009 Jan;103(2):150-3 [19007359.001]
  • [Cites] Lancet. 2009 Mar 28;373(9669):1119-32 [19269025.001]
  • [Cites] Med Oncol. 2009;26(2):202-9 [19229667.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Jun;7(6):645-56 [19555586.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Jun;7(6):659-65 [19555587.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3225-34 [19470934.001]
  • [Cites] Nat Rev Urol. 2009 Jul;6(7):375-83 [19528960.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3584-90 [19487381.001]
  • [Cites] Lancet Oncol. 2009 Aug;10(8):757-63 [19615940.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18722-7 [19850877.001]
  • [Cites] J Clin Oncol. 2009 Dec 1;27(34):5788-93 [19884559.001]
  • [Cites] Annu Rev Med. 2010;61:329-43 [20059341.001]
  • [Cites] Urol Oncol. 2010 Jan-Feb;28(1):69-73 [20123351.001]
  • [Cites] Cancer Invest. 2010 Mar;28(3):312-22 [19863345.001]
  • [Cites] Cancer. 2010 Mar 1;116(5):1272-80 [20082451.001]
  • [Cites] Nat Rev Urol. 2010 May;7(5):277-85 [20448661.001]
  • [Cites] Lancet Oncol. 2010 Jun;11(6):571-8 [20381423.001]
  • [Cites] BJU Int. 2010 Jul;106(2):218-23 [19922542.001]
  • [Cites] Eur Urol. 2009 Dec;56(6):959-71 [19748725.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):425-31 [11208835.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3387-92 [11248088.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):876-82 [11533913.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):966-70 [11583750.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):406-10 [11865300.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):393-400 [11927500.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2376-81 [11981011.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):157-64 [12204536.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1542-52 [12459621.001]
  • [Cites] Oncogene. 2003 Feb 13;22(6):847-52 [12584564.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1214-22 [12663707.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):612-24 [12717246.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2059-67 [12814730.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] J Urol. 2004 Mar;171(3):1071-6 [14767273.001]
  • [Cites] Histopathology. 1986 Nov;10(11):1131-41 [3542784.001]
  • (PMID = 20680492.001).
  • [ISSN] 1776-260X
  • [Journal-full-title] Targeted oncology
  • [ISO-abbreviation] Target Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / BC / Z01 BC011023-01; United States / NCI NIH HHS / BC / Z01 BC011028-01; United States / Intramural NIH HHS / / Z01 BC011023-01; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / BC / Z01 BC011038-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS254814; NLM/ PMC3003336
  •  go-up   go-down


55. Gross-Goupil M, Escudier B: [Targeted therapies: sequential and combined treatments]. Bull Cancer; 2010;97:65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of metastatic kidney cancer has dramatically changed in the last three years, with demonstration of efficacy of sunitinib, sorafenib, temsirolimus, bevacizumab combined with interferon and more recently everolimus.
  • Furthermore, other studies are ongoing to answer other important questions, to optimize the treatment of this disease, such as the role of nephrectomy in case of synchronous metastatic disease, or the efficacy of the targeted therapies in different histological subtype than clear cell carcinoma, or in neoadjuvant and adjuvant settings.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Kidney Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418205.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Benzenesulfonates; 0 / Cytokines; 0 / Indoles; 0 / Interferon-alpha; 0 / Intracellular Signaling Peptides and Proteins; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 624KN6GM2T / temsirolimus; 9ZOQ3TZI87 / sorafenib; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


56. Di Napoli A, Signoretti S: Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer; 2009 May 15;115(10 Suppl):2290-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue biomarkers in renal cell carcinoma: issues and solutions.
  • Renal cell carcinoma (RCC) is an aggressive malignancy that is associated with a high rate of metastasis.
  • Although several promising therapeutic strategies are now available for the treatment of patients with metastatic kidney cancer, the prognosis of these patients remains poor.
  • Research is ongoing to identify RCC-specific biomarkers that can improve early diagnosis, surveillance of tumor progression, and prediction of patient prognosis.
  • Unfortunately, biomarker detection and measurement in kidney tumor tissues can be biased significantly by the lack of standardization in tissue sample acquisition, storage, and analysis.
  • Herein, the authors discuss current issues in tissue-based translational research aimed at identifying clinically useful biomarkers for kidney cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • [Cites] Clin Pharmacol Ther. 2001 Mar;69(3):89-95 [11240971.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):477-83 [18484589.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):172-4 [14983929.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):101-8 [15113684.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):1071-8 [15195116.001]
  • [Cites] Am J Clin Pathol. 1979 May;71(5):483-8 [88175.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1054-9 [8683636.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9 [15569934.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1129-35 [15709180.001]
  • [Cites] Breast Cancer Res Treat. 2005 Mar;90(1):93-6 [15770532.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3714-21 [15897568.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4338-40 [15958615.001]
  • [Cites] Hum Pathol. 2005 Sep;36(9):977-80 [16153460.001]
  • [Cites] J Histochem Cytochem. 2005 Sep;53(9):1167-70 [15956020.001]
  • [Cites] Expert Opin Emerg Drugs. 2005 Nov;10(4):773-95 [16262562.001]
  • [Cites] J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15 [16368942.001]
  • [Cites] Lab Invest. 2006 Feb;86(2):202-11 [16402036.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3381-5 [16585157.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):1026-30 [16831029.001]
  • [Cites] Histopathology. 2006 Oct;49(4):406-10 [16978204.001]
  • [Cites] Histopathology. 2006 Oct;49(4):411-24 [16978205.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1272-7 [16814458.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] J Histochem Cytochem. 2007 Feb;55(2):105-9 [16982846.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):671s-679s [17255292.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s [17255306.001]
  • [Cites] N Engl J Med. 2007 May 31;356(22):2271-81 [17538086.001]
  • [Cites] Ann Oncol. 2007 Jul;18 Suppl 9:ix90-3 [17631603.001]
  • [Cites] Curr Opin Urol. 2007 Sep;17(5):331-6 [17762626.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4757-64 [17947723.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7388-93 [18094421.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):79-83 [17412873.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Mar;65(3):235-62 [17931881.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):377-82 [18300814.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3699-705 [18559586.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • (PMID = 19402057.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA101942
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 44
  • [Other-IDs] NLM/ NIHMS511245; NLM/ PMC3809842
  •  go-up   go-down


57. Karakiewicz PI, Hutterer GC: Predicting outcomes in patients with urologic cancers. Curr Opin Support Palliat Care; 2007 Oct;1(3):153-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: To review the available predictive and prognostic models addressing oncological outcomes in patients with bladder, kidney and prostate cancer.
  • Keywords were 'diagnosis', 'stage', 'prognosis' and 'nomograms' for bladder, kidney and prostate cancer, respectively.
  • SUMMARY: We identified six models for prediction of the natural history of treated bladder cancer.
  • We report on 15 models for patients with kidney cancer.
  • Of these, two preoperative prognostic models predict recurrence-free survival, three postoperative models address disease recurrence, five postoperative models predict disease-specific survival, and, finally, five models predict overall survival in patients with metastatic kidney cancer.
  • For prostate cancer, we found eight models predicting biopsy outcome, 17 models for pretreatment prediction of pathologic stage of clinically localized disease, eight models for prediction of biochemical recurrence, and, finally, six models predicting cancer control outcomes in relapsed or hormone-refractory metastatic prostate cancer.
  • In patients with urologic malignancies, cancer control outcomes can be predicted in a highly accurate and evidence-based fashion.
  • [MeSH-minor] Female. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Male. Prognosis. Treatment Outcome. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685357.001).
  • [ISSN] 1751-4266
  • [Journal-full-title] Current opinion in supportive and palliative care
  • [ISO-abbreviation] Curr Opin Support Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


58. Medhi S, Purandare NC, Dua SG, Gujral S: Bilateral renal metastases in a case of Merkel cell carcinoma. J Cancer Res Ther; 2010 Jul-Sep;6(3):353-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral renal metastases in a case of Merkel cell carcinoma.
  • It is a highly aggressive tumor which commonly metastasizes to lymph nodes, liver, lung and bone.
  • The diagnosis is based on histology and immunohistochemistry.
  • Renal metastasis, with sparing of other common sites of hematogenous spread (lung and liver), is a unique feature of this case.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Kidney Neoplasms / diagnosis. Kidney Neoplasms / secondary. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119275.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


59. Roviello F, Caruso S, Moscovita Falzarano S, Marrelli D, Neri A, Rampone B, De Marco G, Perrotta ME, Mariani F: Small bowel metastases from renal cell carcinoma: a rare cause of intestinal intussusception. J Nephrol; 2006 Mar-Apr;19(2):234-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel metastases from renal cell carcinoma: a rare cause of intestinal intussusception.
  • Small bowel metastases from renal cell carcinoma (RCC) are very rare.
  • We report a case of a 48-year-old female presenting a jejunal intussusception due to intestinal metastasis from RCC.
  • However, if considered in the total summary of reported cases with small bowel metastases from RCC, intussusception is a probable cause.
  • [MeSH-major] Carcinoma, Renal Cell / radiography. Intussusception / radiography. Jejunal Neoplasms / radiography. Kidney Neoplasms / radiography
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16736429.001).
  • [ISSN] 1121-8428
  • [Journal-full-title] Journal of nephrology
  • [ISO-abbreviation] J. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 32
  •  go-up   go-down


60. Assouad J, Masmoudi H, Berna P, Steltzlen C, Radu D, Riquet M, Grunenwald D: Isolated rib metastases from renal cell carcinoma. Interact Cardiovasc Thorac Surg; 2010 Feb;10(2):172-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated rib metastases from renal cell carcinoma.
  • Osseous metastases of renal cell carcinoma (RCC) are the second most frequent location after lung metastases.
  • The purpose of the current study is to focus on a particular subset, the isolated rib metastases (IRM).
  • All had previous radical nephrectomy for clear-cell renal cancer.
  • The mean disease-free interval (DFI) after renal cancer treatment was 25 months.
  • [MeSH-major] Bone Neoplasms / secondary. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Ribs / pathology. Thoracic Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805505.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Langdon J, Way A, Heaton S, Bernard J, Molloy S: The management of spinal metastases from renal cell carcinoma. Ann R Coll Surg Engl; 2009 Nov;91(8):649-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of spinal metastases from renal cell carcinoma.
  • INTRODUCTION: Osseous metastases occur in 50% of patients with renal cell carcinoma; of these, 15% occur in the spine.
  • The treatment options for spinal metastases secondary to renal cell carcinoma are limited.
  • This paper considers the current management options available for spinal metastases secondary to renal cell carcinoma.
  • PATIENTS AND METHODS: A review of four patients with spinal metastases secondary to renal cell carcinoma.
  • RESULTS: The presentation of four cases highlighting the current management options for spinal metastases secondary to renal cell carcinoma.
  • CONCLUSIONS: Historically, spinal metastases from renal cell carcinoma have been poorly managed; however, as the treatment of the primary disease improves, better treatment of the secondary disease is needed.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Spinal Neoplasms / surgery

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spine (Phila Pa 1976). 2001 Jan 15;26(2):151-6 [11154534.001]
  • [Cites] Acta Radiol. 2007 Feb;48(1):89-95 [17325932.001]
  • [Cites] Clin Orthop Relat Res. 2001 Sep;(390):206-11 [11550867.001]
  • [Cites] Acta Orthop Scand Suppl. 2001 Jun;72(302):2p., 1-29 [11582636.001]
  • [Cites] Spine (Phila Pa 1976). 2003 Jul 15;28(14):1549-54 [12865843.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1487-91 [7272969.001]
  • [Cites] Urology. 1981 Dec;18(6):556-61 [7314355.001]
  • [Cites] Spine (Phila Pa 1976). 1983 Nov-Dec;8(8):817-31 [6670016.001]
  • [Cites] J Urol. 1986 Aug;136(2):376-9 [3735498.001]
  • [Cites] J Urol. 1992 Sep;148(3):784-7 [1512825.001]
  • [Cites] Int Orthop. 1994 Oct;18(5):291-8 [7852009.001]
  • [Cites] Am J Clin Oncol. 1997 Aug;20(4):416-8 [9256902.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1103-9 [9305711.001]
  • [Cites] Eur Spine J. 2005 Apr;14(3):250-60 [15480827.001]
  • [Cites] Lancet. 2005 Aug 20-26;366(9486):643-8 [16112300.001]
  • [Cites] Spine (Phila Pa 1976). 2001 Feb 1;26(3):298-306 [11224867.001]
  • (PMID = 19686617.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Cements; 9011-14-7 / Polymethyl Methacrylate
  • [Other-IDs] NLM/ PMC2966239
  •  go-up   go-down


62. Shu Yan Huo A, Lawson Morris D, King J, Glenn D: Use of percutaneous radiofrequency ablation in pulmonary metastases from renal cell carcinoma. Ann Surg Oncol; 2009 Nov;16(11):3169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of percutaneous radiofrequency ablation in pulmonary metastases from renal cell carcinoma.
  • BACKGROUND: Surgical resection of pulmonary metastases from renal cell carcinoma (RCC) has been demonstrated in recent studies to produce good long-term survival outcomes.
  • METHODS: Nine patients had a total of 23 pulmonary metastases treated with percutaneous RFA under fluoro-computed tomography (CT) guidance.
  • RESULTS: A total of 25 ablations were performed to 23 pulmonary metastases for our nine patients in 12 RFA sessions.
  • CONCLUSION: RFA offers a treatment alternative for local tumor control, particularly in selected patients with multiple, small lesions who are unsuitable for pulmonary resections.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Catheter Ablation / instrumentation. Kidney Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2010 Apr;17(4):1214; author reply 1215 [20336818.001]
  • (PMID = 19680727.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Ulmar B, Naumann U, Catalkaya S, Muche R, Cakir B, Schmidt R, Reichel H, Huch K: Prognosis scores of Tokuhashi and Tomita for patients with spinal metastases of renal cancer. Ann Surg Oncol; 2007 Feb;14(2):998-1004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis scores of Tokuhashi and Tomita for patients with spinal metastases of renal cancer.
  • BACKGROUND: Retrospective evaluation of the prognosis scores of Tokuhashi and Tomita for life expectancy in 37 consecutive patients with spinal metastases secondary to renal cancer who underwent surgery.
  • The score of Tokuhashi, composed of six parameters, each rated from zero to two, has been proposed in 1990 for the prognostic assessment of patients with spinal metastases.
  • In 2001, Tomita et al. created another prognostic score, composed of three parameters, growth behaviour of the primary tumor (slow, moderate and rapid) and the evidence of visceral and bony metastases.
  • METHODS: Thirty-seven patients, surgically treated for vertebral metastases secondary to renal cancer were studied.
  • RESULTS: Applying the Tokuhashi Score for the estimation of life expectancy of renal cancer patients with vertebral metastases was found to provide very reliable results with a statistically high significance.
  • CONCLUSION: For surgical decisions in renal cancer patients with spinal metastases, the prognostic score of Tokuhashi appears to be much more valuable than the Tomita score.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Severity of Illness Index. Spinal Neoplasms / surgery

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083006.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Ulmar B, Catalkaya S, Naumann U, Gerstner S, Cakir B, Schmidt R, Reichel H, Huch K: [Surgical treatment and evaluation of prognostic factors in spinal metastases of renal cell carcinoma]. Z Orthop Ihre Grenzgeb; 2006 Jan-Feb;144(1):58-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and evaluation of prognostic factors in spinal metastases of renal cell carcinoma].
  • AIM: The aim of this study was the evaluation of surgical results and prognostic factors in spinal metastases of renal cancer.
  • METHODS: 37 surgical patients with spinal metastases of renal cell carcinoma were retrospectively analysed.
  • For the postoperative survival the Karnofsky-Index and the Frankel-Score were univariate highly significant, the factors nutritional condition and latency between the primary tumor and the development of spinal metastases showed a lower significancy.
  • No prognostical influence for the postoperative survival could be detected for the factors gender, age, localisation of the metastases, type of operation and the factor solitary/multiple metastases.
  • CONCLUSION: In most patients with spinal metastases of renal cell carcinoma, the singular posterior intrumentation combined with a decompression is a sufficient therapy.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / surgery. Spinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498562.001).
  • [ISSN] 0044-3220
  • [Journal-full-title] Zeitschrift für Orthopädie und ihre Grenzgebiete
  • [ISO-abbreviation] Z Orthop Ihre Grenzgeb
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Shimabukuro T, Naito K: Tumor-infiltrating lymphocytes derived from human renal cell carcinoma: clonal analysis of its characteristics. Int J Urol; 2008 Mar;15(3):241-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-infiltrating lymphocytes derived from human renal cell carcinoma: clonal analysis of its characteristics.
  • AIM: To assess the characteristics of activated tumor-infiltrating lymphocytes (TIL), we report the isolation, growth response, and functional analysis of a CD4(-) CD8(+) TIL-clone derived from human renal cell carcinoma (RCC).
  • On day 144, the cytotoxic activity of this clone against the autologous tumor was relatively high (2.3 +/- 0.7 LU(30)/10(6) cells).
  • Meanwhile, against allogeneic renal tumors, there was no cytotoxic activity (-0.1 LU(30)/10(6) cells).
  • CONCLUSIONS: A TIL clone possessing modest autologous tumor-specific cytotoxicity can be isolated from human RCC.
  • The characteristics analysis of various TIL clones may provide a better understanding of an RCC tumor microenvironment and may help to establish new modalities for the treatment of patients with metastatic kidney cancer.
  • [MeSH-major] Carcinoma, Renal Cell. Kidney Neoplasms. Lymphocytes, Tumor-Infiltrating

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304220.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


66. Ricci V, Carbone SF, Testi W, Malatesti R, Lo Gatto M, Dell'Avanzato R, Ginanneschi C, Volterrani L: Single gallbladder and multiple pancreatic metastases from renal cell carcinoma sixteen years after nephrectomy. Chir Ital; 2008 Mar-Apr;60(2):311-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single gallbladder and multiple pancreatic metastases from renal cell carcinoma sixteen years after nephrectomy.
  • We describe a case of female patient presenting with acute biliary symptoms and severe haemobilia due to the presence of a large metastasis in the gallbladder wall from renal cell carcinoma treated by radical nephrectomy 16 years before.
  • CT examination also showed the presence of multiple small round metastases from renal carcinoma in the pancreas, subsequently confirmed surgically and pathologically.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Gallbladder Neoplasms / secondary. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Neoplasms, Second Primary. Nephrectomy. Pancreatic Neoplasms / secondary


67. Ingrosso G, Dandrea M, Miceli R, Benassi M, Giudice E, Di Murro L, Nicolais R, Giubilei C, Di Marzo A, Fedele D, Tortorelli G, Santoni R: Image-guided-radiotherapy retreatment of spine metastasis: a case report and radiobiological evaluation. Tumori; 2010 Sep-Oct;96(5):776-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided-radiotherapy retreatment of spine metastasis: a case report and radiobiological evaluation.
  • AIMS AND BACKGROUND: The present case report describes vertebral metastasis retreatment using kilovoltage cone-beam computed tomography (CBCT) for setup error correction, in order to improve target irradiation and prevent spinal cord toxicity.
  • We evaluated the feasibility of the second radiation therapy course on the overlapping treatment volume.
  • METHODS AND STUDY DESIGN: A patient with metastatic kidney cancer, previously treated to the tenth dorsal vertebra with conventional radiation planning (21 Gy; 3 x 7 Gy), underwent retreatment.
  • In order to deliver 30 Gy (15 x 2 Gy) to the target volume with the second irradiation, we evaluated the residual dose that could be received by the spinal cord.
  • [MeSH-major] Cone-Beam Computed Tomography. Kidney Neoplasms / pathology. Spinal Neoplasms / radiotherapy. Spinal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21302628.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


68. Naito S, Tomita Y, Rha SY, Uemura H, Oya M, Song HZ, Zhong LH, Wahid MI: Kidney Cancer Working Group report. Jpn J Clin Oncol; 2010 Sep;40 Suppl 1:i51-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney Cancer Working Group report.
  • Kidney cancer accounts for approximately 2% of all cancers worldwide, with renal cell carcinoma being the most common form and this report is focused on renal cell carcinoma.
  • Kidney cancer is less common in Asia compared with the West.
  • Cigarette smoking, obesity, acquired cystic kidney disease and inherited susceptibility are known risk factors for kidney cancer.
  • The National Comprehensive Cancer Network Guidelines recommend surgical excision as first line of treatment for Stage I, II or III kidney cancer patients and Stage IV patients with resectable tumours.
  • Immunotherapy has a 20-year history in treatment of metastatic kidney cancer.
  • CONSENSUS STATEMENT: Kidney cancer is relatively uncommon in Asia compared with the West, but its incidence is increasing in more developed Asian nations.
  • Guidelines from the National Comprehensive Cancer Network , etc., for treating metastatic renal cell carcinoma are based on Phase III clinical trials conducted primarily in Western patients.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20870920.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Brookman-May S, May M, Gilfrich C, Wieland WF, Burger M: Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma? Expert Rev Anticancer Ther; 2010 Jun;10(6):813-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
  • Recurrence rates of approximately 35-65% after nephrectomy in patients with localized or locally advanced renal cell carcinoma clearly underline the need for adjuvant treatment modalities.
  • In this trial, targeting the immune system using an autologous tumor-cell vaccine provided clinical efficacy, but as yet, no standard adjuvant therapeutic approach is available.
  • Recent advances in understanding the molecular biology of renal cell carcinoma led to the development of several targeted agents showing antitumor efficacy and prolongation of progression-free survival in patients with metastatic kidney cancer, but to date, no data are available regarding their applicability and efficacy in the adjuvant setting.
  • In this paper, results from current Phase III trials and other relevant studies regarding adjuvant treatment in renal cell carcinoma are reviewed with special interest on adjuvant vaccination therapies, particularly regarding future options of this therapeutic approach.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cancer Vaccines / therapeutic use. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy. Protein-Tyrosine Kinases / antagonists & inhibitors

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20553207.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 59
  •  go-up   go-down


70. Miwa S, Kadono Y, Sugata T, Mizokami A, Namiki M: Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes. Int J Clin Oncol; 2010 Feb;15(1):97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for metastases from renal cell carcinoma with alternation of interferon-alpha subtypes.
  • Here we present a case in which alternation of interferon-alpha (IFN-alpha) treatments was effective in treating pulmonary metastases and lymph node metastases from renal cell carcinoma (RCC).
  • A 56-year-old man underwent left radical nephrectomy under the diagnosis of left RCC.
  • The histological diagnosis was clear cell carcinoma G2, IFN-alpha, pT1b.
  • He subsequently underwent two operations for right pulmonary metastasis and right hilar lymph node metastasis.
  • However, multiple pulmonary metastases and left hilar lymph node metastasis occurred 11 months after discontinuation of Sumiferon.
  • Although OIF was continued for 7 months, pulmonary metastases and left hilar lymph node metastasis continued to progress.
  • Therefore, treatment was changed to Sumiferon, after which the pulmonary metastases and left hilar lymph node metastasis decreased in size.
  • The metastases showed no progression for 16 months after switching from OIF to Sumiferon.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Interferon-alpha / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lymphatic Metastasis
  • [MeSH-minor] Drug Administration Schedule. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20066455.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


71. Esteban-González E, Carballido J, Navas V, Torregrosa Z, Muñoz A, de Mon MA, PortugueseSpanish Inhaled IL-2 Group: Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. Anticancer Drugs; 2007 Mar;18(3):291-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2.
  • Pulmonary metastases of renal cell carcinoma are associated with poor prognosis.
  • Systemic interleukin-2 is used to treat pulmonary metastases of renal cell carcinoma; however, its toxicity limits its use.
  • The objective of this study was to evaluate the efficacy and safety of inhaled interleukin-2 in pulmonary metastases of renal cell carcinoma patients.
  • The study was designed as a retrospective chart review in pulmonary metastases of renal cell carcinoma patients treated with inhaled interleukin-2.
  • Inhaled interleukin-2 shows efficacy and mild toxicity of pulmonary metastases of renal cell carcinoma patients, and might be considered as an alternative treatment to the systemic administration of this drug in these patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Interleukin-2 / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Lung Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264761.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2; 0 / Recombinant Proteins
  •  go-up   go-down


72. Soga N, Yamakado K, Gohara H, Takaki H, Hiraki T, Yamada T, Arima K, Takeda K, Kanazawa S, Sugimura Y: Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma. BJU Int; 2009 Sep;104(6):790-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma.
  • OBJECTIVE: To evaluate the clinical utility of lung radiofrequency ablation (RFA) in patients with unresectable pulmonary metastasis from renal cell carcinoma (RCC).
  • PATIENTS AND METHODS: We retrospectively examined 39 patients with unresectable metastases from RCC who were treated with lung RFA.
  • Patients with six or fewer lung metastases measuring < or =6 cm that were confined in the lung, had all lung tumours ablated (curative ablation).
  • The primary endpoints was the overall survival, secondary endpoints were safety, local tumour progression rate, and recurrence-free survival in the curative ablation group.
  • The maximum lung tumour diameter was also a significant prognostic factor.
  • There was local tumour progression in 13 patients (33%) during the mean follow-up of 25 months.
  • CONCLUSION: Lung RFA is a safe and effective treatment for prolonging survival in patients with unresectable RCC lung metastases.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Catheter Ablation / methods. Kidney Neoplasms. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19338555.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


73. Fottner A, Szalantzy M, Wirthmann L, Stähler M, Baur-Melnyk A, Jansson V, Dürr HR: Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskelet Disord; 2010;11:145
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastases from renal cell carcinoma: patient survival after surgical treatment.
  • BACKGROUND: Surgery is the primary treatment of skeletal metastases from renal cell carcinoma, because radiation and chemotherapy frequently are not effecting the survival.
  • METHODS: We retrospectively reviewed 101 patients operatively treated for skeletal metastases of renal cell carcinoma between 1980 and 2005.
  • RESULTS: 27 patients had a solitary bone metastasis, 20 patients multiple bone metastases and 54 patients had concomitant visceral metastases.
  • Patients with solitary bone metastases had a better survival (p < 0.001) compared to patients with multiple metastases.
  • Age younger than 65 years (p = 0.036), absence of pathologic fractures (p < 0.001) and tumor-free resection margins (p = 0.028) predicted higher survival.
  • Gender, location of metastases, time between diagnosis of renal cell carcinoma and treatment of metastatic disease, incidence of local recurrence, radiation and chemotherapy did not influence survival.
  • CONCLUSIONS: The data suggest that patients with a solitary metastasis or a limited number of resectable metastases are candidates for wide resections.
  • As radiation and chemotherapy are ineffective in most patients, surgery is a better option to achieve local tumor control and increase the survival.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / secondary. Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / secondary
  • [MeSH-minor] Age Distribution. Age Factors. Aged. Disease Progression. Female. Fractures, Bone / epidemiology. Fractures, Bone / pathology. Fractures, Bone / physiopathology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / physiopathology. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / surgery. Prognosis. Retrospective Studies. Severity of Illness Index. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Z Orthop Ihre Grenzgeb. 2006 Jan-Feb;144(1):58-67 [16498562.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1894-900 [16177996.001]
  • [Cites] Clin Orthop Relat Res. 2007 Jun;459:133-8 [17438472.001]
  • [Cites] J Bone Joint Surg Am. 2007 Aug;89(8):1794-801 [17671020.001]
  • [Cites] Clin Orthop Relat Res. 1999 Oct;(367):283-90 [10546626.001]
  • [Cites] J Bone Joint Surg Br. 2000 Jan;82(1):62-7 [10697316.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):115-23 [10768591.001]
  • [Cites] Semin Oncol. 2000 Apr;27(2):160-76 [10768595.001]
  • [Cites] J Urol. 2000 Nov;164(5):1505-8 [11025692.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):379-82 [11445855.001]
  • [Cites] J Bone Joint Surg Br. 2002 May;84(4):521-9 [12043772.001]
  • [Cites] Urology. 2003 Feb;61(2):314-9 [12597937.001]
  • [Cites] Clin Orthop Relat Res. 2003 Apr;(409):223-31 [12671506.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3316-22 [15310775.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6302S-3S [15448021.001]
  • [Cites] J Urol. 1975 Jul;114(1):27-9 [1142493.001]
  • [Cites] Urology. 1978 Jun;11(6):563-7 [675922.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Urology. 1981 Dec;18(6):556-61 [7314355.001]
  • [Cites] Acta Orthop Scand. 1984 Oct;55(5):491-500 [6507069.001]
  • [Cites] J Urol. 1988 Aug;140(2):277-9 [3398121.001]
  • [Cites] Jpn J Clin Oncol. 1989 Jun;19(2):142-8 [2733167.001]
  • [Cites] J Surg Oncol. 1992 Jan;49(1):45-8 [1548881.001]
  • [Cites] J Urol. 1992 Sep;148(3):784-7 [1512825.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1103-9 [9305711.001]
  • [Cites] JAMA. 1999 May 5;281(17):1628-31 [10235157.001]
  • [Cites] Scand J Urol Nephrol. 2004;38(4):299-305 [15669589.001]
  • [Cites] Clin Orthop Relat Res. 2005 Feb;(431):187-92 [15685074.001]
  • [Cites] Eur Urol. 2007 Jul;52(1):163-8 [17098353.001]
  • (PMID = 20598157.001).
  • [ISSN] 1471-2474
  • [Journal-full-title] BMC musculoskeletal disorders
  • [ISO-abbreviation] BMC Musculoskelet Disord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2909163
  •  go-up   go-down


74. Vozmediano-Serrano MT, Toledano-Fernández N, Fdez-Aceñero MJ, Gil-Díez JL, García-Saenz S: Lacrimal sac metastases from renal cell carcinoma. Orbit; 2006 Sep;25(3):249-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lacrimal sac metastases from renal cell carcinoma.
  • PURPOSE: To report the first case of metastasis from renal cell carcinoma to the lacrimal sac and review the therapeutic options.
  • METHODS: We have reviewed the case of a woman who was operated on for a renal cell carcinoma that developed epiphora and a lacrimal sac tumor, which corresponded to a metastasis from her previous tumor.
  • Although renal cell carcinoma shows a great tendency for distant metastasis, this is the first reported case of metastasis to the lacrimal sac.
  • CONCLUSION: Metastasis to the lacrimal sac are rather infrequent and should be borne in mind on the appearance of a tumor in this location in people with a history of malignancy.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Eye Neoplasms / secondary. Kidney Neoplasms / pathology. Lacrimal Apparatus Diseases / etiology


75. Sohaib SA, Cook G, Allen SD, Hughes M, Eisen T, Gore M: Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Br J Radiol; 2009 Aug;82(980):632-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of whole-body MRI and bone scintigraphy in the detection of bone metastases in renal cancer.
  • This study aims to compare the sensitivity of whole-body MRI with bone scintigraphy in the detection of bone metastases in patients with renal cancer.
  • A prospective study was carried out in 47 patients with renal cancer (mean age 62 years, range 29-79 years).
  • The number and sites of bony metastases were assessed on each imaging investigation independently.
  • Sites of extra-osseous metastasis on MRI were also noted.
  • 15 patients (32%) had bone metastases at 34 different sites.
  • MRI identified more metastases in the spine and appendicular skeleton, whereas scintigraphy showed more lesions in the skull/facial and thoracic bones.
  • MRI identified extra-osseous metastases in 33 patients (70%), these were mainly lung and retroperitoneal in site.
  • Whole-body MRI is a more sensitive method for detection of bone metastases in renal cancer than bone scintigraphy, and also allows the assessment of soft-tissue disease.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / secondary. Kidney Neoplasms. Whole Body Imaging / methods

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19221182.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


76. Repiso A, Gómez-Rodríguez R, Aso S, Domper F, Buendía E, González de Frutos C, Pérez-Grueso MJ, Rodríguez-Merlo R, Carrobles JM: [Contribution of endoscopic ultrasound to the diagnosis of pancreatic metastases from renal carcinoma. Apropos of two cases]. Gastroenterol Hepatol; 2007 Mar;30(3):110-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contribution of endoscopic ultrasound to the diagnosis of pancreatic metastases from renal carcinoma. Apropos of two cases].
  • [Transliterated title] Aportación de la ecoendoscopia al diagnóstico de las metástasis pancreáticas del carcinoma renal: a propósito de dos casos.
  • Pancreatic metastases represent 2% of pancreatic tumors.
  • The neoplasms most frequently metastasizing to the pancreas are breast, lung, melanoma and kidney tumors.
  • We present the cases of two patients with pancreatic metastases from renal carcinoma diagnosed 4 and 8 years after the diagnosis and surgical treatment of the primary renal tumor.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / ultrasonography. Endosonography. Kidney Neoplasms. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374322.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


77. Kumar A, Nadig M, Patra V, Srivastava DN, Verma K, Bal CS: Adrenal and renal metastases from follicular thyroid cancer. Br J Radiol; 2005 Nov;78(935):1038-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal and renal metastases from follicular thyroid cancer.
  • Patients with differentiated thyroid cancer may have asymptomatic involvement of renal and/or adrenal gland, particularly if they are elderly and have associated metastases to other organs, which may remain undetected if these patients are not subjected to radioiodine treatment.
  • [MeSH-major] Adenocarcinoma, Follicular / secondary. Adrenal Gland Neoplasms / secondary. Kidney Neoplasms / secondary. Thyroid Neoplasms / surgery


78. Alvarez-Múgica M, Bulnes Vázquez V, Jalón Monzón A, González Alvarez RC, Martín Benito JL, Fernández Gómez JM: [Renal metastasis from an squamous cell carcinoma of the lung. Case report]. Arch Esp Urol; 2007 Dec;60(10):1.197-1.199
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal metastasis from an squamous cell carcinoma of the lung. Case report].
  • [Transliterated title] Metástasis renal de carcinoma epidermoide de pulmón. A propósito de un caso.
  • OBJECTIVE: To report a new case of renal metastasis from an squamous cell carcinoma of the lung.
  • METHODS: A 60 year old male presented to the outpatient office with an ultrasound finding of renal mass.
  • RESULTS: Imaging test studies showed a heterogeneous mass in the upper pole of the left kidney, involving the pelvis and trapping the renal artery.
  • CONCLUSIONS: Clinically recognised or symptomatic metastases to the kidney from pulmonary cancer have been a rare occurrence.
  • Nevertheless, prognosis associated with lung carcinoma metastatic to the kidney is very poor, since the likelihood of a truly solitary metastasis is remote.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Kidney Neoplasms / secondary. Lung Neoplasms / pathology


79. Doh LS, Amato R, Paulino AC, Teh BS: Radiation therapy in the management of brain metastases from renal cell carcinoma. Oncology (Williston Park); 2006 May;20(6):603-13; discussion 613, 616, 619-20 passsim
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy in the management of brain metastases from renal cell carcinoma.
  • Brain metastases from renal cell carcinoma (RCC) cause significant morbidity and mortality.
  • With advances in radiation oncology, stereotactic radiosurgery and hypofractionated stereotactic radiotherapy have been utilized for RCC brain metastases, producing excellent outcomes.
  • This review details the role of radiotherapy in various subgroups of patients with RCC brain metastases as well as the associated toxicities and outcomes.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Carcinoma, Renal Cell / radiotherapy. Kidney Neoplasms / pathology. Neoplasm Metastasis / radiotherapy. Radiation Oncology / trends

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773845.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / Radiation-Sensitizing Agents; 6433A42F4F / motexafin gadolinium; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  • [Number-of-references] 114
  •  go-up   go-down


80. Cánovas Ivorra JA, Castillo Gimeno JM, Burriel Ruiz C, Peláez Malagón S, Michelena Barcena J, Ramírez Daniel A: [Renal metastases of a squamous cell carcinoma of the lung. Case report and bibliographic review]. Arch Esp Urol; 2006 Jun;59(5):526-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal metastases of a squamous cell carcinoma of the lung. Case report and bibliographic review].
  • [Transliterated title] Metástasis renal de carcinoma escamoso de pulmón. A propósito de un nuevo caso y revisión de la literatura.
  • OBJECTIVE: We report a new case of renal metastasis of a lung carcinoma.
  • METHODS: 59-year-old male presenting to the outpatient clinic with a clinical picture compatible with renal colic and hematuria.
  • RESULTS: Ultrasound showed a solid-cystic tumor in the lower pole of the kidney without hydronephrosis.
  • CONCLUSIONS: Renal metastatic lesions of patients with lung cancer present more frequently due to the higher accuracy of radiological tests and have, as well as the primary tumors, very poor survival rates.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Kidney Neoplasms / secondary. Lung Neoplasms / pathology


81. Melegari S, Albo G, Rocco B, Verweij F, Abbinante M, de Cobelli O: Metachronous bladder metastases from renal cell carcinoma: a case report and review of the literature. Ecancermedicalscience; 2010;4:175
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous bladder metastases from renal cell carcinoma: a case report and review of the literature.
  • INTRODUCTION: adrenal gland, parotid gland, pharynx, eye and bladder are rare localizations of metastases of renal cell carcinoma (RCC).
  • We report a case of metachronous RCC metastases to the bladder in a patient with a medical history of transitional cell carcinoma (TCC) of the bladder.
  • The histology of the resected sample was confirmed to be RCC, comparable to a primary kidney cancer and not recurrent TCC.
  • CONCLUSION: the patient had a probability of metastases three years after nephrectomy of 62.9%.
  • Survival rates following single metastasectomy are 60% and 38% at three and five years, respectively; metachronous diagnosis has a better prognosis than synchronous.
  • During RCC follow-up, each lesion should be considered as a possible metastasis of RCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22276029.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3234030
  •  go-up   go-down


82. Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, Yonese J, Fukui I: Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int; 2009 Mar;103(5):620-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate.
  • OBJECTIVE: To investigate the rate of objective response and the skeletal-related event (SRE)-free survival after combined therapy with radiotherapy (RT) and zoledronate in patients with bone metastases from renal cell carcinoma (RCC).
  • PATIENTS AND METHODS: In all, 23 patients with RCC metastatic to bone were included in this retrospective study, of whom 13 had RT to bone metastases with no bisphosphonate therapy between 2000 and 2006, while the remaining 10 had combined therapy with RT and zoledronate (RT + Z) in 2006 and 2007.
  • Significant calcifications of osteolytic metastases and/or shrinkage of bone lesions, as measured by computed tomography, were defined as a partial response.
  • RESULTS: In the RT + Z group, six patients had a partial response, showing evidence of calcification of their osteolytic bone metastases, while in the RT group, only one patient did (P = 0.019).
  • CONCLUSION: Combined therapy as RT + Z achieved a higher objective response rate (six of 10) and prolonged SRE-free survival than RT alone in patients with bone metastases from RCC.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone Neoplasms. Carcinoma, Renal Cell. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Kidney Neoplasms

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2009 Aug;104(3):417-8; author reply 418 [19614659.001]
  • (PMID = 18990143.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


83. Volk A, Kersting S, Konopke R, Dobrowolski F, Franzen S, Ockert D, Grutzmann R, Saeger HD, Bergert H: Surgical therapy of intrapancreatic metastasis from renal cell carcinoma. Pancreatology; 2009;9(4):392-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical therapy of intrapancreatic metastasis from renal cell carcinoma.
  • BACKGROUND: Pancreatic metastases from renal cell carcinoma (RCC) are clinically rare but highly resectable.
  • METHODS: Between January 1996 and December 2007, data from 744 patients were collected in a prospective pancreatic surgery database, and patients with metastasis into the pancreas from RCC were identified.
  • RESULTS: Resective surgery was performed in 14 patients with metastasis to the pancreas from RCC.
  • The median interval between primary treatment of RCC and occurrence of pancreatic metastasis was 94 months (range 32-158).
  • Patients with a metastasis size <2.5 cm had a much better survival after resection (100 months) than those with a metastasis size >2.5 cm (44 months).
  • Moreover, the number of metastases predicts the survival after resection.
  • CONCLUSIONS: In patients with pancreatic metastases from RCC who have only limited disease, complete resection of all lesions can be successfully performed with a low rate of complications.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Pancreas / surgery. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Kaplan-Meier Estimate. Kidney Neoplasms / pathology. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19468247.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


84. Massaccesi M, Morganti AG, Serafini G, Di Lallo A, Deodato F, Picardi V, Scambia G: Late tonsil metastases from renal cell cancer: a case report. Tumori; 2009 Jul-Aug;95(4):521-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late tonsil metastases from renal cell cancer: a case report.
  • The occurrence of renal carcinoma metastasis to the head and neck region is extremely rare.
  • Some authors have reported metastasis of renal cell carcinoma to the parotid glands, nose and paranasal sinus, tongue, larynx, thyroid and palatine tonsil.
  • In this report we describe a rare case of renal cell cancer metastasized to the right tonsil in a 76-year-old man with previously diagnosed bone and lung metastases.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Tonsillar Neoplasms / secondary
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Humans. Lung Neoplasms / secondary. Male

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856668.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


85. Khan T, Chakrabarty A, Baborie A: Renal cell carcinoma in allograft kidney--a case report with unusual findings at autopsy. Int J Urol; 2007 Jul;14(7):652-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma in allograft kidney--a case report with unusual findings at autopsy.
  • A 30-year old male who had a non-related cadaveric renal transplant at the age of 12 years, presented with generalised CNS symptoms and meningeal enhancement on CT scan of the brain, 18 years after the transplantation.
  • Autopsy revealed renal cell carcinoma in the transplanted kidney and metastatic tumour in a variety of organs including the brain.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Kidney Transplantation

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645613.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


86. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW: Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am; 2007 Aug;89(8):1794-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient survival after surgery for osseous metastases from renal cell carcinoma.
  • BACKGROUND: Skeletal metastases from renal cell carcinoma are highly destructive vascular lesions.
  • The goal of this retrospective study was to evaluate factors that may affect survival after surgical treatment of metastases of renal cell carcinoma.
  • METHODS: We performed a retrospective review of a series of 295 consecutive patients who had been treated for metastatic renal cell carcinoma at one institution between 1974 and 2004.
  • A total of 368 metastases of renal cell tumors to the extremities and pelvis were treated.
  • The surgical procedures included curettage with cementing and/or internal fixation (214 tumors), en bloc resection (117), closed nailing (twenty-seven), amputation (four), and other measures (six).
  • The metastatic pattern had a significant effect on the survival rate (p < 0.0001): patients with a solitary bone metastasis had the most favorable overall survival rate.
  • Patients with multiple bone-only metastases had a better survival rate than patients with pulmonary metastases (p = 0.009).
  • The tumor grade did not predict survival (p = 0.17).
  • DISCUSSION: Survival beyond twelve months is possible for a substantial proportion of patients with metastatic renal cell carcinoma.
  • Patients with a clear-cell histological subtype, bone-only metastases, and a solitary metastasis have superior survival rates.
  • The presence of pulmonary metastases does not predict early death in a reliable manner, and some patients may survive for years with pulmonary and systemic disease.
  • [MeSH-major] Bone Neoplasms / secondary. Bone Neoplasms / surgery. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology


87. Nagai T, Igase M, Ochi M, Nagai A, Takada K, Kohara K, Miki T: [Multiple metastases from renal carcinoma 15 years after nephrectomy]. Nihon Ronen Igakkai Zasshi; 2007 Nov;44(6):747-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple metastases from renal carcinoma 15 years after nephrectomy].
  • He underwent left total nephrectomy for renal cell carcinoma (RCC) 15 years previously (in 1990).
  • Since further evaluation yielded no evidence of extra renal metastases, he was followed up in the outpatient clinic.
  • On admission, there was a hard tumor in the right axilla.
  • Ultrasonography demonstrated a vascular tumor with a smooth surface, 26 by 24mm.
  • Laboratory findings were generally close to normal, including tumor markers.
  • Chest contrast-enhanced dynamic CT showed that the tumor was enhanced.
  • Open simple axillary mass biopsy was performed on August 2 and the tumor was histologically confirmed as a metastasis of the RCC to the axillary.
  • His overall status was normal, and he underwent an operation for the pancreas tumor and the tumor in the rectus muscle of the abdomen.
  • On histological examination, both excised specimens were found to be metastases of RCC.
  • During 2 years follow-up period in the outpatient clinic, additional metastasis has not been observed in any organ.
  • Since this case confirms the potential of RCC for late and multiple distant metastases, careful long-term follow-up after radical nephrectomy is needed.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Muscle Neoplasms / secondary. Nephrectomy. Pancreatic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18198458.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


88. Nguyen QN, Shiu AS, Rhines LD, Wang H, Allen PK, Wang XS, Chang EL: Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Mar 15;76(4):1185-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy.
  • PURPOSE: To evaluate the outcomes associated with stereotactic body radiotherapy (SBRT) in the management of spinal metastases from renal cell carcinoma (RCC).
  • METHODS AND MATERIALS: SBRT was used in the treatment of patients with spinal metastases from RCC.
  • Effectiveness of SBRT with respect to tumor control and palliation of pain was assessed using patient-reported outcomes.
  • RESULTS: A total of 48 patients with 55 spinal metastases were treated with SBRT with a median follow-up time of 13.1 months (range, 3.3-54.5 months).
  • The actuarial 1-year spine tumor progression free survival was 82.1%.
  • CONCLUSIONS: The data support SBRT as a safe and effective treatment modality that can be used to achieve good tumor control and palliation of pain associated with RCC spinal metastases.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms. Radiosurgery / methods. Spinal Neoplasms / surgery

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19632064.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Moiseyenko V, Imyanitov E, Danilova A, Danilov A, Baldueva I: Cell technologies in immunotherapy of cancer. Adv Exp Med Biol; 2007;601:387-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell technologies in immunotherapy of cancer.
  • Tumor growth is accompanied by active immune reactions even on the early stages.
  • (1) Optimization of the preparation of autologous and allogeneic antitumor vaccines and development of tumor cell culture bank for the experiments on allogeneic vaccination. (2) Clinical evaluation of autologous vaccine therapy by (a) bone marrow precursors of dendritic cells (DCs), which are loaded with tumor lysates;.
  • (b) genetically modified tumor cells;.
  • (c) intact tumor cells used in combination with various adjuvants (BCG, IL-1beta, and IL-1beta combined with low doses of cyclophosphamide) in patients with disseminated melanoma, metastatic kidney cancer, and colorectal cancer.
  • Clinical trial of genetically modified vaccine included 59 patients (clinical results: I PR (partial response) / 8 SD (disease stabilization)--melanoma, 2 PR/ 2 MR (minimal response) / 3 SD--renal cancer).
  • Vaccine prepared from tumor cell-activated DC bone marrow precursors was administered to 18 patients (clinical results: 2 MR and 6 SD).
  • [MeSH-major] Cancer Vaccines / chemistry. Immunotherapy / methods. Neoplasms / immunology. Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm. Bone Marrow Cells / immunology. Bone Marrow Cells / metabolism. Dendritic Cells / immunology. Female. Humans. Immune System. Immunotherapy, Active. Male. Middle Aged. Models, Biological

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713028.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  • [Number-of-references] 8
  •  go-up   go-down


90. Temsirolimus and mantle cell lymphoma. Highly toxic, limited efficacy. Prescrire Int; 2010 Dec;19(111):276-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mantle cell lymphoma is a highly malignant non-Hodgkin's lymphoma.
  • Temsirolimus, a metabolic precursor of sirolimus, already marketed in the European Union for metastatic kidney cancer, recently received an extension of indications to include relapsed or refractory mantle cell lymphoma.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21355378.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


91. Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA: Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int; 2010 Jul;106(2):218-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present a multi-institutional experience evaluating the use of systemic therapy in patients undergoing cytoreductive nephrectomy (CN), as prospective randomized trials showed a survival benefit for CN in patients with metastatic renal cell carcinoma treated with immunotherapy, and these data have been extrapolated to support CN in the era of targeted therapy, but the likelihood that patients with metastatic kidney cancer who undergo CN will receive systemic treatment afterward remains poorly defined.
  • PATIENTS AND METHODS: In all, 141 patients who underwent CN between 1990 and 2008 were identified from our Institutional Kidney Cancer Registries.
  • The risk of death after surgery correlated with the number of metastatic sites (P = 0.012) and symptoms (P = 0.001) at presentation, poor performance status (P = 0.001), high tumour grade (P = 0.006), and presence of sarcomatoid features (P < 0.024).


92. Mrena R, Leivo I, Passador-Santos F, Hagström J, Mäkitie AA: Histopathological findings in parotid gland metastases from renal cell carcinoma. Eur Arch Otorhinolaryngol; 2008 Sep;265(9):1005-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological findings in parotid gland metastases from renal cell carcinoma.
  • Metastatic tumours involving the parotid gland arising from non-head and neck origin are rare.
  • Immunohistochemistry has improved the differential diagnosis of these lesions.
  • Current immunohistochemical markers allow the distinction between a number of potential primary tumours (e.g., lung, kidney and breast).
  • We present the clinical and histomorphological features of three renal cell carcinoma (RCC) patients presenting with a parotid mass, review the literature of various non-head and neck malignancies metastasizing to the parotid gland, and discuss their differential diagnosis.
  • Two females and one male, aged 58 to 76 years, presented with a parotid tumour of renal cell origin.
  • Two patients underwent a superficial parotidectomy and one patient an open biopsy of the parotid gland tumour.
  • Immunohistochemical stainings for vimentin, CD10 and PNRA were positive suggesting renal cell origin, which was later confirmed.
  • Clinical and radiological evaluations and diagnosis by fine needle aspiration may prove difficult partly due to the vascular nature of parotid metastasis of renal cell carcinoma.
  • Immunohistochemical staining is useful in identifying the primary tumour.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Parotid Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18438681.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


93. Osório L, Sabell F, Soares J, Lima E, Marcelo F: [Vaginal metastasis from renal cell carcinoma]. Actas Urol Esp; 2008 Jun;32(6):653-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vaginal metastasis from renal cell carcinoma].
  • [Transliterated title] Metástasis vaginal de carcinoma de células renales.
  • Vaginal metastases in renal cell carcinoma (RCC) have been reported in rare situations.
  • We present a case of metastatic RCC in a 75-year-old woman, initially presenting with haematuria and vaginal pain.
  • Workup further revealed a renal tumor and a vaginal mass.
  • A nephrectomy and local vaginal excision were performed, leading to the diagnosis of metastatic RCC.
  • Also, because vaginal clear cell carcinoma is rare, all such lesions should be considered potentially renal in origin.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Vaginal Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18655352.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


94. Bandiera A, Melloni G, Freschi M, Giovanardi M, Carretta A, Borri A, Ciriaco P, Zannini P: Prognostic factors and analysis of S100a4 protein in resected pulmonary metastases from renal cell carcinoma. World J Surg; 2009 Jul;33(7):1414-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and analysis of S100a4 protein in resected pulmonary metastases from renal cell carcinoma.
  • BACKGROUND: This study analyzes our experience with pulmonary resection for metastases from renal cell carcinoma.
  • The goals were to search for factors influencing prognosis and to investigate the presence and the prognostic value of S100A4 protein in lung metastases and corresponding primary renal tumors.
  • METHODS: Sixty-five patients underwent surgical resection for renal and pulmonary lesions between 1992 and 2007.
  • S100A4 protein expression was immunohistochemically examined in the peritumoral infiltrate of 64 lesions (32 metastases and the 32 corresponding primary carcinomas).
  • Univariate analysis revealed that surgical radicality (p = 0.0039) and stratification into groups according to the International Registry of Lung Metastases classification (p = 0.0137) were prognostic factors.
  • All metastases and the corresponding primary carcinomas expressed S100A4 protein.
  • Twenty-one metastases (66%) had weak expression and 11 (34%) had strong expression.
  • CONCLUSIONS: Pulmonary resection in metastatic renal cell carcinoma results in long-term survival.
  • Complete resection and stratification into groups according to the International Registry of Lung Metastases classification were prognostic factors.
  • If confirmed in larger studies this finding could be used to schedule adjuvant treatments in patients undergoing nephrectomy for renal cell carcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery. S100 Proteins / metabolism


95. Rades D, Heisterkamp C, Schild SE: Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose? Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):398-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose?
  • PURPOSE: Whole-brain radiotherapy (WBRT) is the most common treatment for brain metastases from renal cell carcinoma (RCC).
  • METHODS AND MATERIALS: Data from 60 patients receiving WBRT for brain metastases from RCC were retrospectively analyzed.
  • Additional factors evaluated were patient age, sex, performance status, number of metastases, interval from diagnosis of RCC to WBRT, extracerebral metastases, recursive partitioning analysis (RPA) class, and year of WBRT.
  • On multivariate analysis, higher WBRT doses (p = 0.022), Karnofsky performance status score ≥70 (p = 0.017), fewer than four brain metastases (p = 0.035), and RPA Class 1 (p = 0.003) resulted in better OS.
  • On multivariate analysis, fewer than four brain metastases (p < 0.001) were associated with LC.
  • CONCLUSIONS: The findings suggest that escalation of the WBRT dose beyond 10 × 3 Gy improves outcomes in patients with brain metastases from RCC.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Carcinoma, Renal Cell / radiotherapy. Cranial Irradiation / methods. Kidney Neoplasms

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20488627.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


96. Stattaus J, Bockisch A, Forsting M, Müller SP: [Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers]. Urologe A; 2005 Jun;44(6):614-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers].
  • [Transliterated title] Wertigkeit der Bildgebung für die Lymphknotenmetastasierung beim Nierenzell-, Blasen-, Prostata- und Peniskarzinom sowie dem Hodentumor.
  • Computed tomography (CT) imaging is the standard method for the assessment of lymph node metastases in renal cell and testicular cancer.
  • In bladder cancer and prostate cancer the results of CT are not convincing due to a large number of false-negative findings and the prognostic relevance of undetected metastases.
  • For both entities recent studies revealed that MR lymphography using iron oxide particles allows the detection of small metastatic lymph nodes.
  • For penile cancer reliable results for imaging of lymph node metastases do not exist.
  • PET with [(11)C] choline and [(11)C] acetate offers great potential in staging and restaging of prostate cancer.
  • [MeSH-major] Lymphatic Metastasis / diagnosis. Magnetic Resonance Imaging / methods. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods. Urogenital Neoplasms / diagnosis
  • [MeSH-minor] Humans. Kidney Neoplasms / diagnosis. Lymph Nodes / pathology. Lymph Nodes / radiography. Lymph Nodes / radionuclide imaging. Male. Penile Neoplasms / diagnosis. Prostatic Neoplasms / diagnosis. Reproducibility of Results. Sensitivity and Specificity. Testicular Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905989.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 61
  •  go-up   go-down


97. Deguchi Y, Shimada K, Nara S, Esaki M, Sakamoto Y, Kosuge T, Hiraoka N: Pancreaticojejunostomy with invagination of the punched pancreatic remnant after medial pancreatectomy and enucleation for multiple metastases of renal cell carcinoma: report of a case. Surg Today; 2009;39(12):1086-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreaticojejunostomy with invagination of the punched pancreatic remnant after medial pancreatectomy and enucleation for multiple metastases of renal cell carcinoma: report of a case.
  • We report the successful resection of multiple pancreatic metastases of renal cell carcinoma (RCC), achieved by performing medial pancreatectomy and enucleation, preserving as much of the pancreatic parenchyma as possible.
  • Considering the unusual behavior of RCC metastasis and the difficulty in predicting the pattern of recurrence, we should devise the optimal surgical strategy to provide cancer-free surgical margins and preserve as much of the pancreatic parenchyma as possible.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Neoplasm Invasiveness / pathology. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery. Pancreaticojejunostomy / methods
  • [MeSH-minor] Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Monitoring, Intraoperative / methods. Neoplasm Staging. Nephrectomy / methods. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19997808.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


98. Nakajima T, Yasufuku K, Wong M, Iyoda A, Suzuki M, Sekine Y, Shibuya K, Hiroshima K, Iizasa T, Fujisawa T: Histological diagnosis of mediastinal lymph node metastases from renal cell carcinoma by endobronchial ultrasound-guided transbronchial needle aspiration. Respirology; 2007 Mar;12(2):302-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological diagnosis of mediastinal lymph node metastases from renal cell carcinoma by endobronchial ultrasound-guided transbronchial needle aspiration.
  • Different radiological modalities are available for the detection of mediastinal lymph node metastases such as multidetector helical CT, PET-scan and PET-CT.
  • However, tissue sampling is required for a firm diagnosis.
  • This method is appropriate not only for cytodiagnosis but also for histological diagnosis.
  • This current study reports a case of mediastinal lymph node metastases from renal cell carcinoma successfully diagnosed histologically by endobronchial ultrasound-guided transbronchial needle aspiration.
  • [MeSH-major] Carcinoma, Renal Cell / ultrasonography. Endosonography. Kidney Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Bronchoscopy. Diagnosis, Differential. Humans. Lymphatic Metastasis. Male. Mediastinum. Middle Aged

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298469.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


99. Yanagawa M, Kuriyama K, Koyama M, Higashiyama M, Tsukamoto Y, Arisawa J, Tomiyama N, Nakamura H: Solitary pulmonary metastases from renal cell carcinoma: comparison of high-resolution CT with pathological findings. Radiat Med; 2006 Dec;24(10):680-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary pulmonary metastases from renal cell carcinoma: comparison of high-resolution CT with pathological findings.
  • PURPOSE: The aim of this study was to examine the radiographic features of solitary pulmonary metastases from renal cell carcinoma by comparing high-resolution CT (HRCT) findings with histopathological observations.
  • MATERIALS AND METHODS: Three thoracic radiologists retrospectively reviewed HRCT findings from eight patients who underwent surgery on the basis of the diagnosis of solitary pulmonary metastatic renal cell carcinoma.
  • The histopathological diagnoses for six of these eight lesions were metastases from clear cell carcinoma of the kidney, one case was a metastasis from papillary renal cell carcinoma, and the remaining case was a metastasis from a poorly differentiated carcinoma including predominantly spindle cells, papillary cells, and clear cells.
  • The HRCT findings for one case of papillary renal cell carcinoma showed a lobulated nodule with a small amount of GGA in an area in the periphery and an air bronchogram.
  • CONCLUSION: In brief, solitary pulmonary metastases from renal cell carcinoma may present as a smoothly marginated nodule, lobulated nodule, or a nodule with peripheral GGA.
  • [MeSH-major] Carcinoma, Renal Cell / radiography. Kidney Neoplasms / pathology. Lung Neoplasms / radiography


100. Sakamoto LH, Mendes W, Pecora M, Andrade RG, Begnani MD, de Camargo B: Bilateral renal metastases from osteosarcoma: A case report and review of the literature. J Pediatr Hematol Oncol; 2006 Sep;28(9):618-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral renal metastases from osteosarcoma: A case report and review of the literature.
  • We report a young adult with OS who developed late bilateral renal relapse.
  • Late recurrences to the kidneys have a more aggressive clinical behavior and poor prognosis documented by 15 cases of OS metastastic to the kidney in the literature.
  • [MeSH-major] Bone Neoplasms / pathology. Kidney Neoplasms / secondary. Osteosarcoma / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Tibia / pathology






Advertisement